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ABSTRACT 
Canine idiopathic pulmonary fibrosis (CIPF) is an incurable fibrosing lung 
disease occurring mainly in West Highland White Terriers (WHWTs). The 
clinical picture of CIPF has many similarities with human idiopathic 
pulmonary fibrosis (IPF). Signs include dry cough, exercise intolerance, and 
respiratory difficulties. Prognosis for CIPF and human IPF is poor, and only 
limited treatment options are available. Histopathological CIPF shares 
features of both human usual interstitial pneumonia (UIP), the pathological 
counterpart of human IPF, and other human idiopathic interstitial 
pneumonia, the non-specific interstitial pneumonia (NSIP). Chronic 
bronchitis (CB) is the main differential diagnosis for CIPF, but antemortem 
differentiation can be challenging, as surgical lung biopsies are seldom taken 
and no clinically useful biomarkers are currently available. The natural 
history of CIPF has not been previously studied and little is known about the 
molecular pathophysiology of CIPF. 
This thesis describes the clinical course, survival, and evaluation of 
exercise intolerance using the 6-minute walk test in CIPF WHWTs. 
Bronchoalveolar lavage fluid (BALF) protein expression was studied to find 
potential biomarkers for CIPF, and aspects of transforming growth factor 
(TGF)-β related molecular pathways in pathogenesis of CIPF were 
investigated. In addition, results of TGF-β signaling activity and its known 
extracellular matrix (ECM) regulatory proteins, latent TGF-β binding protein 
(LTBP)-1 and fibrillin-2, in CIPF were compared with findings in human 
IPF/UIP and NSIP. 
The follow-up study showed that CIPF has a significant negative impact 
on life expectancy of diseased dogs. The median CIPF-specific survival after 
onset of clinical signs in WHWTs was 2.7 years, but individual survival varied 
considerably from only a few months to over 4 years. This variance indicates 
that CIPF may have either a slow or a rapid disease progression, as also seen 
in human IPF. In addition, during the disease course acute exacerbations 
(AEs) occurred. The 6-minute walk distance proved to be an easy and 
noninvasive parameter to evaluate lung function and level of exercise 
intolerance in CIPF WHWTs. No significant prognostic factors were 
identified. 
The quantitative comparison of BALF proteomes obtained from CIPF 
WHWTs, CB dogs, and healthy dogs revealed similar changes for CIPF and 
CB, which suggests a common response to disease processes in these 
otherwise different lung diseases. Specific biomarkers for CIPF were not 
identified.  
The immunohistochemical stainings suggested that increased TGF-β 
signaling and its ECM regulatory proteins LTBP-1 and fibrillin-2 are part of 
the molecular pathophysiology of CIPF, as also seen in human IPF/UIP and 
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NSIP. We demonstrated strong expression of activin B, a member of the 
TGF-β superfamily, in the altered alveolar epithelium of WHWTs with CIPF. 
Furthermore, activin B was detected in BALF of CIPF WHWTs, most notably 
in samples from dogs with AE, but not in BALF of healthy WHWTs. This 
novel finding suggests that activin B is part of the CIPF pathophysiology and 
might act as a potential marker of alveolar epithelial damage. 
Our findings add important new knowledge about the natural history and 
molecular pathophysiology of CIPF in WHWTs and show similarities 
between CIPF and human IPF. Better understanding of the complex 
pathogenesis of CIPF and human IPF is crucial for developing novel 
diagnostic tools and treatment strategies for these yet incurable diseases. 
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1 INTRODUCTION 
The primary function of the canine respiratory system, consisting of upper 
and lower respiratory components, is gas exchange in which oxygen and 
carbon dioxide are transported between the environment and the tissues. 
Other functions of the respiratory system include thermoregulation, 
metabolism of endogenous and exogenous substances, and protection 
against inhaled particles and infectious agents. The canine lower respiratory 
tract comprises the trachea, the main bronchi, and the right and left lung. 
Ventilation passes air through the trachea and bronchial tree into the 
terminal air spaces of the respiratory system, the alveoli, where the gas 
exchange between the air and blood occurs. The air-blood barrier consists of 
a thin layer of surfactant lining the alveolar surface, the alveolar epithelial 
layer formed by flattened squamous type I cells (alveolar epithelial cell, 
AECI) and cuboidal type II cells (AECII), alveolar basal lamina, variable 
thickness interstitium, and capillary endothelium (Figure 1). The diffusion of 
oxygen and carbon dioxide occurs through a thin portion of the alveolar-
capillary complex, where the type I cell is separated from the capillary 
endothelial cell by a single basal lamina shared by the two cell types (Ross et 
al. 1995, Robinson 1997). 
 
Figure 1 Illustration of oxygen (arrow to right) and carbon dioxide (arrow to left) diffusion 
between the alveolus (ALV) and red blood cell (RBC) within the pulmonary capillary 
(Cap). AECI/II, alveolar epithelial cell type I/II; BL, basal lamina; E, capillary 
endothelium; I, interstitium. 
 11 
Normal tissue repair is essential to allow tissues and organs to recover after 
an insult caused by a wound or a disease. The acutely or moderately injured 
tissue or organ should in the normal healing process be almost completely 
restored. However, if the injury persists, an impaired remodeling process 
with excess extracellular matrix (ECM) deposition, mainly collagen, occurs, 
causing fibrosis and organ dysfunction (Micallef et al. 2012). Altered ECM 
and fibrotic diseases of various organs, including the heart, kidney, liver, and 
lung, have been reported in dogs (Ide et al. 2001, Spee et al. 2006, Aupperle 
et al. 2009, Syrjä et al. 2013) as well as in humans (Blobe et al. 2000).  
Canine idiopathic pulmonary fibrosis (CIPF) is a breed-predisposed 
disease of unknown etiology, occurring particularly in West Highland White 
Terriers (WHWTs) (Norris et al. 2005). In humans, idiopathic pulmonary 
fibrosis (IPF) is considered to be a consequence of repeated alveolar 
epithelial injury of unknown cause, leading to an abnormal repair process 
and accumulation of collagen in the pulmonary interstitium (King et al. 
2011). The thickened interstitium hampers gas exchange and eventually leads 
to respiratory failure in both human IPF (Katzenstein et al. 2008) and CIPF 
(Norris et al. 2005). Clinical and histopathological features of CIPF in 
WHWTs and their resemblance to features of human IPF have been reported 
earlier (Heikkilä et al. 2011a, Syrjä et al. 2013). However, the natural course 
of CIPF has not been previously described, and little is known about its 
pathogenesis. In addition, noninvasive diagnostic tools, such as biomarkers 
from blood or bronchoalveolar lavage fluid (BALF), would be highly 
beneficial for CIPF diagnostics since high-resolution computed tomography 
(HRCT) or lung biopsies are not widely available in clinical veterinary 
practice. Revealing the complex pathogenetic mechanisms of CIPF and 
human IPF is critical for development of novel treatment strategies, as 
currently no curative treatment for these fatal diseases exists and the 
causative agents are unknown (Heikkilä et al. 2011a, Raghu et al. 2011). 
The purpose of this thesis was to describe the natural course of CIPF in 
WHWTs, to uncover potential biomarkers, and to elucidate the molecular 
pathogenesis of CIPF. 
 
Review of the literature 
12 
2 REVIEW OF THE LITERATURE 
2.1 IDIOPATHIC PULMONARY FIBROSIS (IPF) 
2.1.1 DEFINITION, HISTOPATHOLOGICAL FEATURES, AND 
PATHOGENESIS 
IPF, both in dogs (Norris et al. 2005, Heikkilä et al. 2011a) and in humans 
(Raghu et al. 2011), is a progressive, fibrosing lung disease of unknown cause 
affecting primarily the pulmonary interstitium.  In dogs, it appears to be 
breed-specific, occurring mainly in terriers, most notably in WHWTs 
(Corcoran et al. 1999, Lobetti et al. 2001, Heikkilä et al. 2011a). In man, most 
cases of IPF are considered to be sporadic and the familial forms account for 
less than 5% (Raghu et al. 2011). An IPF-like condition has also been 
reported in cats (Cohn et al. 2004, Williams et al. 2004), and a distinct form 
of pulmonary fibrosis, equine multinodular pulmonary fibrosis associated 
with equine herpesvirus 5, has been described in horses (Williams et al. 
2007, 2013).  
The main histopathological finding in WHWTs with CIPF is mature 
diffuse interstitial fibrosis of the alveolar walls (Syrjä et al. 2013). The 
histopathological pattern of IPF in humans is usual interstitial pneumonia 
(UIP). The IPF/UIP belongs to the group of idiopathic interstitial 
pneumonias, and its differentiation from the very similar subtype of 
idiopathic interstitial pneumonia, the non-specific interstitial pneumonia 
(NSIP), and especially from its fibrosing form, can be difficult (Katzenstein et 
al. 2008, Meltzer and Nobel 2008). The cellular form of NSIP is 
characterized by a chronic inflammatory cell infiltrate with minimal fibrosis, 
and its differentiation from UIP is usually straightforward (Katzenstein et al. 
2008). CIPF in WHWTs shares histopathological features of both UIP and 
fibrotic NSIP (Syrjä et al. 2013). For clinical and histopathological 
terminology, see Table 1. The diffuse interstitial fibrosis and variable grade of 
interstitial inflammation seen in CIPF resemble fibrosing NSIP 
histopathologically, but the alveolar architectural distortion (i.e. honeycomb 
change), seen in areas of more severe fibrosis in CIPF is typical of UIP 
(Katzenstein et al. 2008, Syrjä et al. 2013). Fibroblastic foci, which are 
composed of fibroblasts and myofibroblasts and indicate an active, ongoing 
disease process, are characteristic of human UIP (Katzenstein et al. 2008), 
but are not seen in CIPF (Syrjä et al. 2013). 
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Table 1 Clinical and histopathological terminology. 
Clinical diagnosis Histopathological picture 
IPF UIP 
NSIP fibrosing NSIP or cellular NSIP 
CIPF CIPF 
IPF, idiopathic pulmonary fibrosis; UIP, usual interstitial pneumonia; NSIP, non-specific interstitial 
pneumonia; CIPF, canine idiopathic pulmonary fibrosis. 
The pathogenesis of human IPF is still incompletely understood, but evolving 
evidence indicates that the pathogenesis is epithelial-driven (King et al. 
2011). Repeated injuries to alveolar epithelial cells with subsequent 
destruction of the alveolar basement membrane lead to aberrant epithelial 
repair (Coward et al. 2010).  While many factors have been proposed to 
contribute to the epithelial injury, such as environmental factors, chronic 
viral infections, and chronic silent gastroesophageal microaspiration, the 
etiology of human IPF remains unknown (King et al. 2011).  In reaction to 
the injurious agent, the AECI cells, which normally constitute more than 90% 
of alveolar wall area and are responsible for gas exchange, undergo apoptosis 
(Prasse and Müller-Quernheim 2009).  As AECI cells are unable to replicate, 
accumulation of hyperplastic AECII cells occurs as a regenerative attempt. 
The repetitively activated AECII cells produce a variety of growth factors and 
chemokines, most notably transforming growth factor (TGF)-β1, leading to 
excess ECM formation and development of IPF (Coward et al. 2010). 
Autoimmune disorders have been suggested to have role in the pathogenesis 
of idiopathic NSIP (Romagnoli et al. 2011). 
As marked atypia of AECII has been shown to be a consistent finding in 
lungs of CIPF WHWTs, it is likely that AECs and possibly exhaustion of their 
reparative capacity are important in the pathogenesis of CIPF (Syrjä et al. 
2013). Microarray analyses of gene expression profiles in lungs of dogs with 
CIPF have revealed several potential genes that take part in the pathogenesis 
of CIPF (Krafft et al. 2013). The biological functions associated with these 
genes are related to cellular growth and proliferation, inflammation and 
immune response, and developmental processes (Krafft et al. 2013). In 
addition, activation of TGF-β1 pathways (Krafft et al. 2012) and upregulation 
of collagenolytic matrix metalloproteinase-9 (Heikkilä et al. 2011b) have been 
suggested to take part in the pathogenesis of CIPF. The higher serum TGF-β1 
concentrations observed in healthy WHWTs relative to other breeds might 
partly explain the breed susceptibility for CIPF (Krafft 2011a, Krafft et al. in 
press). 
Review of the literature 
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2.1.2 CLINICAL FEATURES AND DIAGNOSIS 
CIPF affects mainly middle-aged to older WHWTs and causes gradually 
worsening respiratory signs, including dry cough and exercise intolerance 
(Corcoran et al.1999, Heikkilä et al. 2011a). In addition, pulmonary 
hypertension is a relatively common complication seen in WHWTs with CIPF 
(Schober and Baade 2006). Clinical diagnosis of CIPF can be challenging, as 
clinical signs are nonspecific and slowly developing. The condition can be 
confused with other respiratory diseases, especially chronic bronchitis (CB), 
and with cardiac diseases (Corcoran et al. 1999). Tentative diagnosis is done 
based on signalement and clinical findings featuring velcro crackles on 
auscultation, low arterial partial pressure of oxygen, increased alveolar-
arterial oxygen gradient, and a moderate to severe bronchointerstitial pattern 
in thoracic radiography. Additional diagnostics includes bronchoscopy and 
bronchoalveolar lavage (BAL) for eliminating differential diagnoses and 
HRCT to further confirm the CIPF diagnosis in the absence of surgical lung 
biopsy (Corcoran et al.1999, Johnson et al. 2005, Heikkilä et al. 2011a). As 
antemortem surgical biopsies are seldom taken from dogs, histopathological 
confirmation of the diagnosis is usually performed after death (Johnson et al. 
2005).  
Human IPF patients experience exertional dyspnea, chronic dry cough, 
finger clubbing, and bibasilar inspiratory crackles on auscultation (Raghu et 
al. 2011). The disease occurs with older age, the mean age at presentation 
being 66 years.  As in dogs, the slow onset of symptoms can be attributed to 
aging or other cardiac or respiratory diseases, delaying the diagnosis for 
several months to years (Meltzer and Noble 2008).  In humans, diagnosis of 
IPF requires the presence of a UIP pattern on HRCT in patients not subjected 
to surgical lung biopsy (Raghu et al. 2011). The natural history of human IPF 
varies. Most patients have a gradual decline in functional status after 
diagnosis, but some may have a rapidly progressive disease course or a step-
like progression, in which periods of relative stability are interrupted by 
acute exacerbations (AEs) (Kim et al. 2006). AEs of IPF are defined as 
combination of sudden worsening of dyspnea within 30 days with new lung 
infiltrates in HRCT and no evidence of pulmonary infection or other 
underlying cause, such as pulmonary embolism or left heart failure (Collard 
et al. 2007). AEs are associated with high mortality and a histopathological 
pattern of diffuse alveolar damage (DAD) (Rice et al. 2003, Kim et al. 2006, 
Ley et al. 2011). DAD has also been demonstrated in WHWTs with CIPF, 
along with consequent organizing luminal fibrosis, suggesting that more 
rapid progression of the fibrosis through organizing DAD can occur in dogs 
as well (Syrjä et al. 2013).  
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2.1.3 SIX-MINUTE WALK TEST (6MWT) FOR EVALUATION OF 
EXERCISE TOLERANCE 
The six-minute walk test (6MWT) is a submaximal exercise test commonly 
used to measure functional exercise capacity before and after medical 
intervention in human patients with a moderate or severe heart or lung 
disease. It can also be used to measure one-time functional status and even 
predict the mortality from heart or lung disease (ATS 2002, Enright 2003). 
In dogs, the use of 6MWT has been assessed in a limited number of studies 
with healthy dogs (Ferreira et al. 2010, Gault et al. 2010, Swimmer and 
Rozanski 2011), dogs with induced congestive heart failure (Boddy et al. 
2004), and dogs with various pulmonary diseases (Swimmer and Rozanski 
2011). The 6MWT has been found to be an easy and reproducible test for 
screening exercise tolerance. 
The test is considered safe and reflects well the activities of daily living 
(ATS 2002, Enright 2003). The primary outcome is the distance walked 
(6MWD). In addition, other measurements, such as oxygen desaturation 
using pulse oximetry and in humans level of fatigue or dyspnea, can be 
obtained before, during, and after 6MWT (ATS 2002, Enright 2003). The 
6MWT is widely used in clinical practice to evaluate human IPF patients and 
has been shown to be a reliable, valid, and responsive measure of exercise 
tolerance in IPF patients (du Bois et al. 2011). Desaturation during the test 
and the distance walked have been linked to increased risk of death in IPF 
patients (Lama et al. 2003, Caminati et al. 2009). In addition, in human IPF 
patients, a decline of 24-45 m over 6 months represents a clinically 
important difference in the risk of death at 1 year, and this change could be 
used as a guideline for change in therapy or as an endpoint in clinical trials 
(du Bois et al. 2011). In dogs, the distance walked has been shown to decrease 
after an induced heart failure (Boddy et al. 2004), and dogs with respiratory 
disease walked shorter distances than healthy dogs (Swimmer and Rozanski 
2011). However, in the latter study, the dogs suffering from different 
respiratory diseases were older and of smaller breed than controls (Swimmer 
and Rozanski 2011). Age- and breed-matched controls are important when 
comparing 6MWD results in dogs, as leg length and age are associated with 
walking distance (Enright 2003, Swimmer and Rozanski 2011). No studies 
reporting the use of 6MWT as a prognostic factor or as a measurement of 
treatment outcomes in dogs with lung or heart disease have been published. 
2.1.4 SURVIVAL AND PROGNOSTIC FACTORS 
The median survival of WHWTs with CIPF has been reported in a 
retrospective study to be 16 months from the onset of clinical signs and 7 
months from diagnosis, but CIPF is speculated not to shorten the life 
expectancy since the disease affects middle-aged to older WHWTs (Corcoran 
et al. 1999). In humans, median survival of IPF patients from diagnosis is 
only 2-3 years, however, this might be underestimate in some patient groups 
Review of the literature 
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(Raghu et al. 2011). Fibrotic NSIP has a better prognosis, median survival 
being 6-13.5 years (Kim et al. 2006), and the cellular form has an excellent 
long-term outcome (Park et al. 2009).  
No prognostic factors affecting the survival of WHWTs with CIPF have 
been published. In human IPF, the search for prognostic factors has been 
extensive since the course of the disease can vary greatly among patients, 
from rapidly to slowly progressive to a step-like process (Kim et al. 2006). 
Several factors have been associated with poor survival in humans, including 
decreased walking distance in 6MWT (Caminati et al. 2009), increasing 
grade of interstitial fibrosis on thoracic radiographs  (Schwartz et al.1994), 
fibrosis score, and traction bronchiectasis in thin-section computed 
tomography (Sumikawa et al. 2008), increased BAL neutrophilia (Kinder et 
al. 2008), and the presence of pulmonary hypertension (Andersen et al. 
2012).  
2.1.5 TREATMENT OPTIONS 
Very limited information is available regarding treatment options for CIPF. 
Medications commonly used to treat CIPF include corticosteroids, 
bronchodilators, and antimicrobials (Corcoran et al.1999). It is currently 
unknown whether these medications have an effect on the clinical course of 
CIPF, but lung fibrosis in humans is unresponsive to these commonly used 
medications (Raghu et al. 2011). However, many dogs with CIPF have 
concurrent bronchial changes (Heikkilä et al. 2011a, Syrjä et al. 2013) and 
some seem to respond to corticosteroid treatment (Corcoran et al.1999). In 
addition, the majority of patients with NSIP are treated with corticosteroids 
and cytotoxic agents and seem to benefit from these (Park et al. 2009). If 
pulmonary hypertension is present, sildenafil, which has been evaluated in 
the treatment of pulmonary hypertension in dogs (Brown et al. 2010), can be 
tried. 
The benefits of the first and as yet only antifibrotic drug, pirfenidone, in 
human patients with IPF have been demonstrated in many clinical trials in 
recent years (Azuma et al. 2005, Noble et al. 2011, King et al. 2014). 
Pirfenidone reduces the decline in lung function and prolongs progression-
free survival (Noble et al. 2011, King et al. 2014). The exact receptor for 
pirfedidone is unknown, but it has combined anti-inflammatory, antioxidant, 
and antifibrotic effects in experimental models of fibrosis, as it regulates the 
activity of TGF-β and tumor necrosis factor-α, and inhibits fibroblast 
proliferation and collagen synthesis (Iyer et al. 1999, Di Sario et al. 2002, 
Nakazato et al. 2002). Although the phamacokinetics of pirfenidone in dogs 
has been evaluated (Bruss et al. 2004), no reports on its clinical use in dogs 
exist, and the high price of the drug will (likely) hinder treatment trials. In 
addition to pirfenidone, one of the most important recent discoveries in the 
therapeutic field of human IPF has been that the previously used standard 
triple therapy (prednisone, azathioprine, and N-acetylcysteine) was 
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demonstrated to be harmful, possibly due to the toxic actions of the 
immunosuppressive agents, and is no longer used to treat IPF (Raghu et al. 
2012, Martinez et al. 2014). Nintedanib, a triple tyrosine kinase inhibitor, has 
recently been shown to slow disease progression in human IPF patients 
(Richeldi et al. 2014). Lung transplantation is an appropriate option for only 
some IPF patients (Raghu et al. 2011). Despite recent therapeutic advances, 
IPF is a fatal disease and improving the outcomes for IPF patients remains a 
challenge (Raghu and Thickett 2013). 
2.1.6 SEARCH FOR POTENTIAL BIOMARKERS 
According to the Biomarkers Definition Working Group (2001), a biological 
marker (biomarker) can be defined as follows: “a characteristic that is 
objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention”. However, the term nowadays usually refers to molecular or 
biochemical markers (Frangogiannis 2012). An optimal biomarker should be 
noninvasive and easy to obtain, e.g. by blood sampling or urine collection, 
and it should be able to be analyzed using standard measurement techniques 
(Veenstra et al. 2005, Prasse and Müller-Quernheim 2009). The epithelial 
lining fluid collected during BAL reflects the airway protein composition and 
makes it a suitable material for a biomarker search in lung diseases (Lenz et 
al. 1990, Noël-Georis et al. 2001, Wattiez and Falmagne 2005, Magi et al. 
2006). Modified protein expression in human BALF for various respiratory 
diseases, including IPF, has been reported (Noël-Georis 2001, Magi et al. 
2002, Wattiez and Falmagne 2005), but no BALF proteomic studies 
regarding canine lung disease have been previously published.  
The search for disease-specific biomarkers in BALF or serum of humans 
with IPF has been extensive in recent years (Kinnula et al. 2009, Prasse and 
Müller-Quernheim 2009). A biomarker that could distinguish between UIP 
and NSIP, reflect disease activity, or predict who will have IPF in the future 
would be most beneficial (Prasse and Müller-Quernheim 2009, Vij and Noth 
2012). Unfortunately, although numerous biomarkers have been proposed 
for human IPF, none have yet been validated or implemented in clinical 
practice (Kinnula et al. 2009, Prasse and Müller-Quernheim 2009, Vij and 
Noth 2012). In dogs, as HRCT is not widely available in clinical veterinary 
practice for confirming CIPF diagnosis, and surgical biopsies are seldom 
taken, noninvasive biomarkers from blood or BALF are even more needed. 
Currently, for CIPF, serum and BALF endothelin-1 (ET-1) concentrations 
(Krafft et al. 2011b), BALF procollagen type III amino terminal peptide 
(PIIINP) concentrations (Heikkilä et al. 2013), and serum chemokine (C–C) 
ligand 2 (CCL2) (Krafft et al. 2013) have been proposed as potential 
biomarkers. ET-1, a vasoactive, profibrotic and proinflammatory peptide, 
PIIINP, a marker of enhanced collagen turnover and fibroblast activity, and 
CCL2, an inflammatory cytokine, are also found to be elevated in BALF and 
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serum of humans with IPF (Uguccioni et al. 1995, Lammi et al. 1999, 
Reichenberger et al. 2001, Capelli et al. 2005). PIIINP concentrations in 
BALF and ET-1 concentrations in serum and BALF could also help to 
differentiate CIPF from its main differential diagnosis, CB (Krafft et al. 
2011b, Heikkilä et al. 2013).  
Proteomics, defined as a large-scale characterization of proteins 
expressed by a genome (Andersson and Anderson 1998), can be used to 
identify biomarkers and reveal disease-specific mechanisms from different 
biofluids (Veenstra et al. 2005, Prasse and Müller-Quernheim 2009). The 
main proteomic approaches used are gel-based (2DE), gel-free (mass 
spectrometry), and protein chip methods (Kinnula et al. 2009). The BALF 
proteome reflects far better the local environment in the lung than the 
plasma/serum proteome and is therefore an ideal material for lung 
proteomic studies (Wattiez and Falmagne 2005). However, up to 89% of the 
BALF proteome is, in health and disease, composed of high-molecular-
weight plasma-derived proteins such as albumin and immunoglobulins 
(Govender et al. 2007). The major challenge of BALF proteomics is that these 
highly abundant proteins can interfere with the detection of pathologically 
relevant proteins present in low amounts (Kinnula et al. 2009). It is generally 
considered that these low-abundance proteins are produced locally by lung 
epithelial cells, and therefore, they are more pathologically relevant 
(Govender et al. 2007).  Two-dimensional differential gel electrophoresis, 
2D-DIGE, offers a reliable technique for quantitative analysis of complex 
protein samples such as BALF (Magi et al. 2006).  
 
2.2 TRANSFORMING GROWTH FACTOR (TGF)-β 
SUPERFAMILY 
2.2.1 MEMBERS OF THE TGF-β SUPERFAMILY 
The first members of the TGF-β superfamily were discovered in the 1980s, 
and since then, more than 40 members of this polypeptide family have been 
identified (Santibañez et al. 2011). The TGF-β superfamily can be divided to 
several subfamilies, including TGF-βs, activins/inhibins, bone 
morphogenetic proteins, growth and differentiation factors, and Müllerian 
inhibitory factors.  All of these family members share similar dimeric 
structure and participate in different aspects of cell differentiation, immune 
regulation, inflammation, tissue homeostasis, and embryonic development 
(Santibañez et al. 2011).  
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2.2.2 TGF-β STORAGE, ACTIVATION, AND SIGNALING IN LUNGS 
In mammals, three structurally related, highly conserved isoforms of TGF-β, 
TGF-β 1, 2, and 3, are expressed and secreted by almost all cell types (Blobe 
et al. 2000, Santibañez et al. 2011). Although all three isomers are expressed 
by the lung, only TGF-β1 has been associated with fibrotic response in tissue 
samples from human IPF patients (Khalil et al.1996, Coker et al. 2001) and in 
animal models (Coker et al.1997, Ask et al. 2008). 
All TGF-βs are produced as inactive latent complexes, consisting of a 
mature TGF-β and a latency-associated protein (LAP), which are unable to 
associate with their receptors. TGF-β is cleaved from LAP before it is secreted 
by the cell, but it remains attached to LAP by non-covalent bonds forming a 
small latent complex. This complex then binds to latent TGF-β binding 
protein (LTBP), forming a large latent TGF-β complex, which is then secreted 
by the cell and bound to ECM (see Figure 2) (Taipale et al. 1994, Koli et al. 
2001, 2008).  
  
Figure 2 A schematic picture of a large latent TGF-β complex (LLC) consisting of dimeric 
TGF-β, latency-associated protein (LAP), and latent TGF-β binding protein (LTBP) 
bound to extracellular matrix (ECM) fibers (modified from Koli et al. 2008). 
The latent TGF-β-1 has been shown to be associated with the ECM via LTBP-
1 (Taipale et al. 1994). LTBPs form together with fibrillins the LTBP/fibrillin 
ECM protein family (Hyytiäinen et al. 2004). LTBPs have an important role 
in the targeting of large latent complexes to ECM, and this way also regulate 
the storage and the activation process of TGF-βs (Koli et al. 2001, 2008). 
LTBP-1 has been found to be significantly upregulated in human IPF patient 
lungs (Leppäranta et al. 2012). Fibrillin-1 is the major component of 
connective tissue microfibrils. It has been shown to be associated with LTBP-
1 and to regulate the storage and bioavailability of TGF-β-1 (Isogai et al. 
2003, Chauldry et al. 2007, Massam-Wu et al. 2010). The expression of 
fibrillin-2 has been shown to participate in the wound healing process, 
although its expression is mainly considered to be restricted to developing 
fetal tissues (Brinckmann et al. 2010). Aberrant activation of developmental 
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pathways is typical for IPF (Selman et al. 2008), and fibrillin-2 has recently 
been shown to be activated in adult fibrotic lungs (Leppäranta et al. 2012).  
In normal tissue homeostasis, considerable amounts of TGF-β are stored 
in the ECM as latent complexes. In healthy lungs, TGF-β-1 is mostly in latent 
form, in contrast to fibrotic lungs, where it is active (Xu et al. 2003, Koli et al. 
2008,). The activation process of TGF-β is characterized by the release of 
TGF-β from the latent complex by the action of different proteases, including 
plasmin and MMPs, thrombosponding, integrin, or reactive oxygen species 
(Annes et al. 2003). After extracellular activation, the binding of TGF-βs to 
cell receptors leads to phosphorylation of signaling proteins Smad2 and 
Smad-3, which then bind to Smad4. The activated Smad complex moves to 
the nucleus, where it regulates the target gene transcription (see Figure 3) 
(Blobe et al. 2000, Chauldry et al. 2007). In addition, non-Smad-dependent 
pathways exist (Moustakas and Heldin 2005). 
 
  
Figure 3 A schematic picture of intracellular TGF-β signaling mediated by the Smad family of 
proteins. Binding of TGF-β (circles) to type II TGF-β receptor (RII) results in RI 
binding to the complex and phosphorylation (indicated by triangles) of RI. This leads 
to phosphorylation of signal transducer proteins Smad2/3, which then bind to 
Smad4 and the complex moves to the nucleus (modified from Blobe et al. 2000, Shi 
and Massague 2003). 
2.2.3 ROLE OF TGF-β IN DEVELOPMENT AND TISSUE HOMEOSTASIS 
TGF-β family members have a key role in embryogenesis, where they induce 
epithelial-mesenchymal transition (EMT) leading to normal organogenesis 
(Derynck and Akhurst 2007, Selman et al. 2008). The most important 
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functions of TGF-β in normal tissue homeostasis are the regulation of cell 
proliferation (i.e. inhibition of growth and induction of apoptosis), induction 
of ECM synthesis (i.e. induction of ECM proteins, such as collagen, and 
increasing the expression of proteinase inhibitors that degrade the ECM), 
and inhibition of the immune system (Hyytiäinen et al. 2004). 
2.2.4 TGF-β IN FIBROTIC DISEASES 
When the balance in the interactions between the ECM and cells is disturbed, 
a disease can result. ECM synthesis is upregulated in the normal wound 
healing process, but if inappropriate activity of TGF-β occurs, due to 
persistent injury or failed repair, it can lead to excessive ECM formation and 
fibrosis (Blobe et al. 2000, Coward et al. 2010). 
Activation of the TGF-β pathway has been shown in lungs of CIPF dogs 
(Krafft et al. 2012), in canine hepatic fibrosis (Spee et al. 2006), and in 
canine mitral valve disease (Aupperle et al. 2008).  
TGF-β1 has profound effects on epithelial cells and fibroblasts, which are 
central to the pathogenesis of human pulmonary fibrosis (Coward et al. 
2010). Abnormal TGF-β regulation and function have also been linked to 
many other human diseases, including chronic obstructive pulmonary 
disease, liver cirrhosis, glomerulonephritis, atherosclerosis, and cancer 
(Blobe et al. 2010, Santibañez et al. 2011).  
TGF-β1 overexpression, mainly from AEC in IPF, is responsible for 
fibroblast proliferation and transformation into myofibroblasts, which in 
turn cause the exaggerated accumulation of ECM (fibrosis) and contribute to 
basement membrane disruption and epithelial cell death (Coward et al. 2010, 
King et al. 2011, Micallef et al. 2012). TGF-β is also the major inducer of EMT 
in adult tissue (Willis and Borok 2007). EMT is featured by epithelial cells 
losing many of their epithelial characteristics and obtaining properties of 
mesenchymal cells, giving rise to fibroblasts and myofibroblasts (Willis and 
Borok 2007). EMT has been shown to be reinstated in cancer and fibrosis 
processes (Derynck and Akhurst 2007, Selman et al. 2008). In addition, 
TGF-β1 is a potent inducer of lung epithelial cell apoptosis (Hagimoto et al. 
2002) and promotes lung epithelial cell migration (Yu et al. 2008) and lung 
fibroblast collagen synthesis (Raghu et al. 1989).  
2.2.5 ACTIVINS 
Activins are members of the TGF-β superfamily of cytokines. Activin A was 
first identified in 1980s as an inducer of follicle-stimulating hormone (FSH) 
secretion from the anterior pituitary (Liang et al. 1986, Vale et al. 1986). 
Several activin subunits have since been discovered, but biological activities 
of activin A, B, and AB have been described best (Hedger et al. 2011).  
Published data on the role of activins in canine normal and pathological 
tissue processes are sparse, but activins have been reported to be involved in 
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regulation of the estrus cycle of the bitch (Marino et al. 2003) and to be 
produced by Leydig cells in adult male testis (Marino and Zanghi 2013). 
Activins are greater than 97% conserved across species, implying their 
high individual functional importance (Hedger and de Kretser 2013). Activin 
A is a homodimer of two βA subunits, and activin B is a homodimer of two βB 
subunits. These subunits are encoded by genes named inhibin beta A 
(INHBA) and INHBB (Hedger and de Kretser 2013). Inhibins, in contrast, 
suppress FSH secretion. They are heterodimers comprising β and α subunits, 
and their expression is mainly limited to gonads and to a lesser extent to the 
pituitary gland, placenta, adrenal gland, and central nervous system (Hedger 
and de Kretser 2013). 
Since its discovery, activin A has been shown to be involved in a variety of 
inflammatory, repair, and fibrotic processes, in addition to its reproductive 
roles (Matsuse et al. 1996, Aoki et al. 2005, de Kretser et al. 2012). Most 
published studies have concentrated on the role of activin A in acute and 
chronic inflammatory processes, but importance of activin B in these 
processes has also been suggested (de Kretser et al. 2012). After binding of 
activins to activin-specific transmembrane type II receptors, the type I 
receptor, usually activin receptor-like kinase 4, phosphorylates, which leads 
to intracellular Smad2/3 signaling and cellular effects (Bernard et al. 2006). 
This Smad2/3 signaling pathway is common to TGF-βs (Hedger and de 
Kretser 2013). Activin B has also been demonstrated to bind to another type I 
receptor, ALK-7 (Bernard et al. 2006), as well as to signal through the P-
Smad1/5/8 pathway (Besson-Fournier et al. 2012). Follistatin is the major 
endogenous activin inhibitor, which can block the biological activities of 
activin (Aoki et al. 2005).  
In the lung, activins have a role in the developmental processes (Zhao et 
al. 1996), and activin A has also been suggested to participate in the 
pathophysiology of human pulmonary fibrosis (Matsuse et al.1996, de 
Kretser et al. 2012), asthma (Karagiannidis et al. 2006) and acute respiratory 
distress syndrome (ARDS) (Apostolou et al. 2012). The role of activin A in 
the lung fibrosis process is supported by its ability to promote proliferation of 
airway smooth muscle cells (Cho et al. 2003) and proliferation of lung 
fibroblasts and their differentiation into myofibroblasts (Ohga et al. 1996). 
Furthermore, follistatin has been shown to attenuate acute lung injury in the 
early phase and later fibrosis in a bleomycin-induced pulmonary fibrosis 
model in mice (Aoki et al. 2005), and an activin A neutralizing protein was 
found to reduce acute alveolar injury in LPS-challenged mice (Apostolou et 
al. 2012). Overexpression of Activin-A has been demonstrated to induce 
ARDS-like pathology in experimental mouse ARDS (Apostolou et al. 2012). 
Pathogenesis of ARDS is characterized by DAD and consists of three 
distinctive phases, early, proliferating, and fibrotic (Castro 2006, DeClue and 
Cohn 2007). ARDS is also recognized in dogs and can be secondary to 
various etiological factors (DeClue and Cohn 2007).  
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3 AIMS OF THE STUDY 
Aims of this thesis were as follows: 
 
1. To describe the natural course of CIPF in WHWTs and to 
evaluate survival, prognostic factors, and exercise intolerance in 
CIPF WHWTs (Study I). 
 
2. To evaluate the bronchoalveolar lavage fluid proteome of CIPF 
WHWTs, dogs with chronic bronchitis, and control dogs to 
determine whether different protein expression profiles exist 
and to reveal potential biomarkers (Study II). 
 
3. To investigate the role of TGF-β, the major profibrotic molecule 
of human IPF, its extracellular matrix regulatory proteins, 
LTBP-1 and fibrillin2, and activins, members of the TGF-β 
superfamily, in the molecular pathobiology of CIPF in WHWTs 
(Studies III and IV). 
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4 MATERIALS AND METHODS 
4.1 ETHICAL APPROVAL FOR STUDY PROTOCOLS 
The study protocols of privately owned, prospectively recruited healthy and 
CIPF WHWTs were approved by the Committee of Experimental Animals of 
Western Finland (ESHL-2008-05403/Ym-23) and the Ethics Committee for 
Animal Experimentation at the University of Helsinki (5B/2008) (Studies I, 
II, III, and IV). 
The laboratory beagles (Study II) were part of a university research colony 
and were housed and cared for in accordance with the guidelines of the 
Ethics Committee for Animal Experimentation at the University of Helsinki 
(HY132-05). 
The use of retrospectively retrieved lung samples (Studies III and IV) 
from the archives of the Department of Pathology and Parasitology at the 
Faculty of Veterinary Medicine, University of Helsinki, and the use of leftover 
BALF samples stored from client-owned CB dogs (Study II) at the University 
of Helsinki Veterinary Teaching Hospital were approved by ownersfor 
research purposes.  
Human lung UIP and NSIP samples (Study III) were acquired with 
informed consent either from lungs explanted during lung transplantation or 
from diagnostic biopsies. The study protocol was approved by the Ethics 
Committee of Helsinki University Central Hospital (Permission no. 
426/13/03/01/09), Helsinki, Finland. 
4.2 SAMPLE POPULATION 
Total number of animals: The study population consisted of 22 WHWTs with 
CIPF and 13 healthy WHWTs. In addition, samples from 5 dogs of other 
breeds with CB (Study II), 4 healthy beagles (Study II), 4 dogs of other 
breeds with ARDS (Study IV), 5 human cases with UIP, and 6 human cases 
with NSIP (Study III) were used. 
Confirmation of disease and health in WHWTs: All CIPF WHWTs were 
prospectively recruited. CIPF was confirmed histopathologically in 21/22 
CIPF WHWTs and by HRCT in 1/22 (still alive). For healthy WHWTs, 11/13 
were prospectively recruited animals and 2/13 were retrospectively retrieved 
lung samples. The health status of 11 control WHWTs (Study I) was 
confirmed with history and thorough physical and clinical examinations. 
None of the control WHWTs showed signs or findings indicative of 
pulmonary disease and 1/11 was also in later necropsy confirmed to be 
healthy (lung tissue sample used in Studies III and IV).  For the two 
retrospectively retrieved control WHWT lung samples (used in Studies III 
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and IV), the reasons for euthanasia were intestinal intussusception and joint 
disease. These two dogs had a complete necropsy examination performed, 
which revealed no findings, histopathological or otherwise, related to lung 
disease. 
Study I: Dogs included in the clinical follow-up and prognostic factor 
study consisted of 15 CIPF WHWTs and 11 healthy WHWTs that were 
prospectively recruited during 2007-2012 and followed until death or study 
endpoint (September 2012), at the Veterinary Teaching Hospital of the 
University of Helsinki, Finland. 
The median age of the CIPF WHWTs (7 intact males, 2 intact females, 1 
neutered male, 5 neutered females) at the time of presentation was 12 (range 
8-13) years. The median age of the healthy control WHWTs (3 intact males, 1 
intact female, 7 neutered females) at the time of presentation was 9 (range 6-
13) years. 
Study II: The study material for proteomic analysis consisted of BALF 
samples obtained from 6 WHWTs with histopathologically confirmed CIPF, 5 
dogs of other breeds that were confirmed to have CB on the basis of results of 
the clinical examinations performed to exclude other causes of clinical signs, 
and 4 clinically and later histopathologically confirmed healthy laboratory 
beagles. 
The CIPF WHWTs were aged 11-15 (mean 12) years at the time of sample 
collection. The CB dogs were aged 2-11 (mean 10) years at the time of 
diagnosis and sample collection and were of 5 breeds (one of each of the 
following: Labrador Retriever, Cairn Terrier, Australian Shepherd Dog, 
Welsh Gorgi, and English Springer Spaniel). The Beagles were aged 5-9 
(mean 7) years.  
Study III: The study material for immunohistochemistry consisted of lung 
samples from 14 CIPF WHWTs, 3 WHWTs without lung disease, 5 human 
cases with UIP, and 6 human cases with NSIP.  All of the canine lung samples 
were necropsy samples taken after euthanasia.  
At the time of tissue sampling, the median age of the CIPF WHWTs was 
13 (range 10-16) years. The three control WHWTs were aged 2, 6 
(retrospective samples), and 13 years at the time of euthanasia. Human 
patients with biopsy-proven UIP were a median age of 59 (range 40-68) 
years and those with NSIP 54.5 (range 45-69) years. 
Study IV: The sample population consisted of 4 WHWTs with CIPF and 
concurrent AE, 6 WHWTs with CIPF but no AE, 4 dogs of different breeds 
with ARDS, and 8 WHWTs without lung disease. All 4 WHWTs with CIPF 
and AE were euthanized due to dyspnea and histopathologically had DAD. 
Five of the six WHWTs with CIPF but no AE were euthanized due to non-
CIPF-related causes and one due to worsening cough. None of the 6 had DAD 
histopathologically. All 4 ARDS dogs had histopathological changes 
consistent with DAD. 
For immunohistochemistry, necropsy samples from 4 WHWTs with CIPF 
and concurrent AE, 5 WHWTs with CIPF but no AE, 4 dogs with ARDS, and 
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3 WHWTs without lung disease were used. At the time of tissue sampling, 
the median age of the CIPF dogs was 13 (range 10-15) years. The four ARDS 
dogs (retrospective samples) were 2.5, 3, and 4 months and one 7 years of 
age, and the three control WHWTs were 2, 6 (retrospective samples), and 13 
years at the time of euthanasia and tissue sampling. The ARDS dogs were of 
4 different breeds (one each of King Charles Spaniel, Miniature Bull Terrier, 
French Bulldog, and Norfolk Terrier). The suspected underlying etiology of 
ARDS was in two cases aspiration, in one case upper airway obstruction and 
in one case idiopathic ARDS.  
For Western blot analysis, BALF samples from 2 WHWTs with CIPF and 
concurrent AE, 4 WHWTs with CIPF but no AE, and 6 healthy control 
WHWTs were used. BALF samples from WHWTs with CIPF were collected 
either immediately after euthanasia (4/6) or at the time of diagnosis (2/6). 
The median age of the WHWTs with CIPF at the time of sample collection 
was 14 (range 11-15) years. The median age of the 6 healthy control WHWTs 
was 8 (range 7-13) years at time of sample collection. One control sample was 
collected immediately after euthanasia, 5 samples at time of study inclusion. 
4.3 CLINICAL INFORMATION OF DISEASED AND 
HEALTHY WEST HIGHLAND WHITE TERRIERS 
(WHWTS) AND SELECTION CRITERIA FOR 
PROGNOSTIC PARAMETERS  
The clinical examinations of WHWTs with CIPF in the clinical follow-up 
study (Study I) were performed as described previously (Heikkilä et al. 
2011a). Briefly, the diagnostic evaluation at the time of presentation 
consisted of history and physical examination (15/15), hematology and serum 
biochemistry (15/15), fecal examination (14/15), arterial blood gas analysis 
(15/15), thoracic radiography (15/15), echocardiography (13/15), high-
resolution computed tomography (HRCT) (10/15), and bronchoscopy and 
BAL (9/15). After the initial visit, the dogs were followed in control visits at 
3- to 6-month intervals and additionally as needed. At control visits, a 
physical examination, hematology and serum biochemistry, arterial blood 
gases, and thoracic radiography were performed. Diagnosis of CIPF was 
confirmed by histopathology in 13 deceased animals, as described in Syrjä et 
al. (2013), and by HRCT in two dogs still alive at the study endpoint. 
The causes of death were divided for survival analysis purposes into CIPF-
related (defined as euthanasia due to acute dyspnea or severe progression of 
respiratory signs) or non-CIPF-related. The onset of clinical signs was 
defined as the time-point when the owner first noticed respiratory signs or 
exercise intolerance. 
Parameters representing possible prognostic factors predicting survival of 
CIPF dogs were chosen among the clinical information collected at the time 
of diagnosis. Only parameters that were available for at least ten diseased 
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animals and that had previously been shown to be altered in WHWTs with 
CIPF (Heikkilä et al. 2011a, Krafft et al. 2011b) were chosen. The parameters 
analyzed included partial pressures of oxygen (PaO2) and carbon dioxide 
(PaCO2) in arterial blood, alveolar-arterial oxygen gradient (P(A-a)O2), 
serum ET-1 concentration, severity of changes in thoracic radiographs, and 
HRCT Hounsfield unit values. These parameters were analyzed as previously 
described (Heikkilä et al. 2011a, Krafft et al. 2011b). In addition, prognostic 
value of rate of change in arterial blood gas (PaO2, PaCO2, and P(A-a)O2) 
and complete blood cell count values (hemoglobin, hematocrit, erythrocytes, 
mean corpuscular volume, neutrophils, lymphocytes, eosinophils, 
monocytes, and thrombocytes) between the first and last available 
measurement in CIPF-related death were analyzed. These analyses were 
performed for those diseased animals that had at least one control visit 
(12/15) before death or study endpoint.  
For control WHWTs, similar clinical examinations as for WHWTs with 
CIPF were performed. Dogs representing the same age group as WHWTs 
with CIPF, middle-aged to older, were chosen. The health status of control 
WHWTs was confirmed with history and physical examination (11/11), 
hematology and serum biochemistry (11/11), fecal examination (10/11), 
arterial blood gas analysis (11/11), thoracic radiography (11/11), 
echocardiography (10/11), HRCT (8/11), and bronchoscopy and BAL (8/11). 
Ten dogs were included in the survival analysis. Follow-up was performed by 
control visits (3/10) or by contacting the owner by telephone after the study 
endpoint (7/10). 
4.4 6MWT  
To evaluate exercise tolerance in CIPF WHWTs relative to healthy WHWTs, 
the 6MWT was performed on 6 WHWTs with CIPF at the time of diagnosis 
and on 5 healthy control WHWTs (Study I). The WHWTs were part of the 
follow-up study population. The test was repeated in five WHWTs with CIPF 
during their control visits. The dogs were walked along a quiet 63.5-m 
straight corridor on a leash at their own pace, for six minutes. The 6MWD 
was recorded in meters and heart rate, body temperature, oxygen saturation 
(SpO2) by pulse oximetry, and arterial blood gases were measured before 
and after walking.  
4.5 BRONCHOALVEOLAR LAVAGE FLUID (BALF) 
COLLECTION AND SAMPLE PROCESSING 
Bronchoscopy, BAL, and sample processing (Studies II and IV) were 
performed as described by Heikkilä et al. (2011a). Briefly, BAL was 
performed during bronchoscopy in dogs anesthetized intravenously or 
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immediately after euthanasia. The right and left caudal lung lobes were 
lavaged with warm (37°C) saline (0.9% NaCl) solution (2 mL/kg, divided into 
2 aliquots), and the samples were immediately processed for further analyses 
and then frozen at –80°C. 
4.6 ASSAYS 
4.6.1 TWO-DIMENSIONAL DIFFERENTIAL GEL ELECTROPHORESIS 
For proteomic analysis of BALF samples from CIPF WHWTs, CB dogs, and 
control dogs (Study II), 2D-DIGE was performed. 
The BALF samples were thawed, prepared for proteomic analysis and 
labeled with cyanine dyes as described in the manufacturer´s protocol. The 
labeled samples were separated via 2D-DIGE as described elsewhere (Ünlü et 
al. 1997). 
Immobilized pH gradient strips were used for isoelectric focusing. They 
were loaded with 150 μg of protein by use of a cup-loading method. 
Isoelectric focusing was performed (IPGPhor, GE Healthcare, Uppsala, 
Sweden), and after completion, second-dimension gel electrophoresis was 
conducted with 12% sodium dodecyl sulfate-polyacrylamide (SDS-PAGE) 
gels. Gels were scanned between low-fluorescence glass plates (FLA-5100 
laser scanner, Fujifilm, Tokyo, Japan). After gels were scanned, they were 
stained with silver stain without aldehyde (PlusOne silver staining kit, GE 
Healthcare, Uppsala, Sweden). The gel images were analyzed and statistically 
assessed (DeCyder, version 7.0, GE Healthcare, Uppsala, Sweden). 
After image analysis, protein spots of interest were manually excised from 
the gels and digested in gel with trypsin (Sequencing grade modified trypsin, 
V5111, Promega, Madison, WI, USA), as described elsewhere (Shevchenko et 
al. 1996, Jensen et al. 1998). Samples were concentrated and desalinated 
(C18 trap column, SGE Analytical Science, Griesham, Germany), followed by 
mass spectrometry analysis. LC-MS/MS of peptides was performed on a 
hybrid quadrupole–TOFMS with a nanospray source (QSTAR Elite, Applied 
Biosystems, Foster City, CA, USA). Identification of proteins was performed 
with a local MASCOT (Matrix-Science, London, UK) search engine, against 
an in-house database of published canine sequences. The results were 
evaluated by considering the probability score, sequence coverage, and 
correspondence between the estimated and experimental isoelectric point 
and molecular weight. 
4.6.2 IMMUNOHISTOCHEMISTRY  
Selection of lung samples for immunohistochemistry of CIPF WHWTs 
(Studies III and IV) was done as described in Syrjä et al. (2013). In brief, one 
slide from the paraffin block with 1-3 lung sections having lesions most 
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compatible with UIP in man based on hematoxylin and eosin staining was 
selected for each CIPF case. For CIPF samples representing AE and for ARDS 
samples (Study IV), lung sections displaying DAD were selected. 
Antibodies used for immunohistochemical staining in Study III were 
polyclonal rabbit antibody against P-Smad2/3 (Ser465/467, Millipore, 
illerca, MA, USA), mouse monoclonal antibody against LTBP-1 (MAb388, 
R&D Systems, Minneapolis, MN, USA), and mouse monoclonal antibody 
against fibrillin-2 (clone 48, Millipore, Temecula, CA, USA). In Study IV, 
these were mouse monoclonal antibodies (mAbs) against human activin-A 
(mAb 18/26A) and activin-B (mAb 12/9A) subunits (encoded by INHBA and 
INHBB genes, respectively) generated by AnshLabs LLC (Webster, TX, USA).  
Paraffin-embedded lung tissue sections were deparaffinized in xylene and 
rehydrated in graded alcohol. Antigens were retrieved by heating the sections 
in 0.01 M citrate buffer in a microwave oven until the solution came to a boil 
and then for a further 10 min. The solution was left to cool down to room 
temperature. For immunostaining, the Novolink Polymer Detection System 
(Novocastra, Leica Biosystems Newcastle Ltd., Newcastle Upon Tyne, UK) 
was used according to the manufacturer´s protocol. Endogenous peroxidase 
activity was blocked with 3% hydrogen peroxide. The sections were exposed 
to the primary antibody at 4°C overnight (P-Smad2 diluted 1:500, LTBP-1 
diluted 1:100 and fibrillin-2 diluted 1:800, Study III) or in room temperature 
for 1.5 hours (activin A diluted 1:100 and activin B diluted 1:200, Study IV). 
The bound antibodies were visualized by using diaminobenzidine (DAB). The 
sections were counterstained with Mayer´s hematoxylin and mounted on 
glass slides. The specificity of the staining was confirmed by using specific 
isotype controls for each antibody (Rabbit Isotype Control and Mouse 
Isotype Control; Invitrogen, Carlsbad, CA, USA). For all staining, control 
sections were negative. 
4.6.3 WESTERN BLOT ANALYSIS 
Verification of 2D-DIGE results (Study II) was performed with Western blot 
analysis.  Altogether, 20 µL of each sample was separated by 12% SDS-PAGE 
and transferred to a nitrocellulose membrane via a semidry blotting 
apparatus (Bio-Rad, Hercules, CA, USA).  Membranes were blocked with 5% 
bovine serum albumin in 20 mM Tris–HCl, 150 mM NaCl, and 0.1% Tween-
20 at room temperature. Membranes were then incubated overnight at 4°C 
with primary antibody (anti-apolipoprotein A-1, anti-β-actin, anti-C3, or 
anti-haptoglobin) in Tris-buffered saline solution with Tween, which was 
followed the next morning by incubation with an appropriate secondary 
antibody conjugated with alkaline peroxidase. Colorimetric development of 
bound immunocomplexes was performed, and Western blot bands were 
photographed (Alphalmager HP system, Alpha Innotech Corp., San Leandro, 
CA, USA). 
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Detection of activin B in BALF of CIPF and healthy WHWTs was 
performed with Western blotting (Study IV). Recombinant activin B (R&D 
Systems, Minneapolis, MN, USA) was used as a positive control. BALF 
samples were thawed and then concentrated. SDS-PAGE electrophoresis was 
carried out in 4-15% polyacrylamide gradient gels (Mini-PROTEAN TGX 
Precast Gels, Bio-Rad, Hercules, CA, USA) using a vertical slab gel apparatus 
under non-reducing conditions (Mini-PROTEAN Tetra Cell, Bio-Rad). 
Altogether, 25 µL of each sample was separated by electrophoresis, after 
which proteins were transferred to a polyvinylide difluoride membrane 
(Hybond-P, PVDF Transfer Membrane, GE Healthcare, Uppsala, Sweden) 
via a tank blotting apparatus (Mini Trans-blot®, Bio-Rad). Membranes were 
blocked with 10% skim milk in 0.1% Tween/TBS at room temperature. 
Membranes were then incubated overnight at 4°C with primary antibody 
(anti-activin B) in 2.5% skim milk in 0.1% Tween/TBS, followed the next 
morning by incubation with an appropriate secondary antibody conjugated 
with horseradish peroxidase (Polyclonal Goat Anti-Mouse 
Immunoglobulins/HRP, Dako, Denmark A/S).  Bound immunocomplexes 
were visualized (SuperSignal West Dura Substrate, Thermo Scientific, 
Rockford, IL, USA), and bands were imaged using chemiluminescent 
scanning (LAS-3000, FUJIFILM, Tokyo, Japan). 
4.7 STATISTICAL METHODS 
Descriptive statistics are presented as median and range for all studies. All 
comparisons were performed as two-tailed tests. A P-value of  <0.05 was 
considered significant. 
Study I: Statistical analyses were conducted using SAS System for 
Windows, version 9.3 (SAS Institute Inc., Cary, NC, USA) and SPSS 20.0 for 
Mac (SPSS Inc., Chicago, IL, USA). 
Both CIPF-specific and all-cause survival times were calculated. In the 
CIPF-specific analysis, dogs were censored if they were alive (2 WHWTs) or 
had died due to a non-IPF-related cause (6 WHWTs). For the all-cause 
survival analysis, dogs were only censored if they were alive. The all-cause 
survival of WHWTs with CIPF against the control group was compared with 
Kaplan-Meier (KM) survival curves and estimated together with Cox 
proportional hazards models. The Cox model was adjusted for the dog´s age 
at the time of diagnosis/study inclusion.  
For prognostic factor analysis, KM curves and Cox regression analysis 
were performed for categorical variables (radiographic values) and Cox 
regression for continuous variables. The survival time was calculated from 
onset of clinical signs. Hazard ratios (HRs) with 95% confidence intervals 
(CIs) were calculated for all models. The effects of rate of change on repeated 
measure parameters from the time of diagnosis to the last available 
measurement on CIPF-related death were assessed with logistic regression 
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models. Odds ratios (ORs) with 95% CIs were calculated to quantify the 
results.  
For 6MWT results, Mann-Whitney U-test was used to compare 
differences between control and diseased animals, and Kendall`s tau-b 
correlation coefficient was used for correlations. Wilcoxon signed-rank test 
was used for all paired samples in 6MWT and for comparisons between 
initial and last available clinical measurements. 
Study II: 2D-DIGE gel images were analyzed and statistically assessed 
(DeCyder, version 7.0, GE Healthcare, Uppsala, Sweden). Protein spots that 
had a minimum 1.5-fold difference in mean spot volume ratios in all 
biological replicates were tested via an ANOVA. If differences were detected, 
the Student’s t test was applied to compare differences in data between 
healthy control dogs and dogs with IPF and between healthy control dogs 
and dogs with CB. Proteins with a value of P < 0.05 were selected for 
identification. 
Studies III and IV: Semiquantitative immunohistochemical staining data 
were analyzed with SPSS 20.0 for Mac (SPSS, Chicago, IL, USA). Pairwise 
comparisons for Study III groups were performed using non-parametric 
Mann-Whitney U-test. Comparisons between study groups in Study IV were 
performed using non-parametric Kruskal-Wallis with subsequent pairwise 
comparisons using the Dunn test. Kendall´s tau-b correlation coefficient was 
used for correlations (Study III).  
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5  RESULTS 
5.1 CLINICAL FINDINGS DURING DISEASE 
PROGRESSION AND CAUSE OF DEATH AND 
RELATED HISTOPATHOLOGIC FINDINGS 
Of the 15 WHWTs with CIPF included in the follow-up study (Study I), 12 
had at least one control visit before death or study endpoint. A significant 
decrease occurred between the first (median 58.9 mmHg, range 50.6–64.0 
mmHg) and the last (median 50.0 mmHg, range 44.3–51.5 mmHg) PaO2 
values (P= 0.04) and a significant increase between the first (median 54.8 
mmHg, range 43.5–67.4 mmHg) and the last (median 70.9 mmHg, range 
57.6–80.8 mmHg) P(A-a)O2 measurement (P=  0.04) in all 5 CIPF WHWTs 
that had died of CIPF-related causes. During the disease course temporary 
improvements were noted in PaO2 values in 7/12 WHWTs with CIPF. The 
magnitude of these improvements varied from 2.8 mmHg to 19.9 mmHg, 
with a median of 7.9 mmHg. No significant change was noted in body weight 
of 12 WHWTs with CIPF between the first (median 9.9 kg, range 7.8–11.9 kg) 
and last (median 9.6 kg, range 7.2–11.8 kg) measurement (P= 0.31) or 
between the first (median 50%, range 44-61%) and last (median 51%, range 
35-64%) hematocrit values (P= 0.18). The bronchointerstitial radiographic 
changes were initially classified as severe in 7/12 animals or moderate in 5/12 
animals. In 6 animals, no change in pattern severity was seen, in 3 the 
classification changed from moderate to severe, and in 3 it changed from 
severe to moderate during disease progression. Three animals had an 
alveolar pattern at the time of diagnosis, but not at the last control visit, and 
5 dogs with no alveolar pattern at the first visit had it at the last control visit. 
Seven of 13 deceased WHWTs with CIPF died of CIPF-related causes. Five 
of these 7 dogs were euthanized due to dyspnea and 2 due to severe 
progression of respiratory signs. Four of the 5 dyspneic dogs showed acute 
alveolar damage (DAD) histopathologically. Causes of death or euthanasia in 
the non-CIPF-related death group (6 dogs) were pyelonephritis, metastatic 
mammary tumor, drowning, acute uremia, acute vomiting, and 
hemoabdomen. The dog that drowned also had DAD in the lungs. Three of 
the control WHWTs were euthanized before the study endpoint. The reasons 
were dementia in one dog, mammary tumor in another, and unknown in the 
third. None of the control WHWTs had any owner-reported respiratory signs 
before death or study endpoint. 
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5.2 SURVIVAL AND PROGNOSTIC FACTORS  
The median follow-up time of 15 CIPF WHWTs included in the follow-up 
study (Study I) was 15 (range 0–40) months, and the median follow-up time 
of 10 control WHWTs was 35 (range 6–55) months. 
Thirteen of 15 CIPF WHWTs were euthanized during the study period and 
2 were still alive at the study endpoint. The median all-cause and CIPF-
specific survival times of deceased WHWTs from birth, from onset of clinical 
signs, and from time of diagnosis are presented in Table 2. All-cause survival 
refers to death or euthanasia due to CIPF and non-CIPF-related causes 
together and CIPF-specific survival to death or euthanasia due to only CIPF-
related causes. The median survival of deceased control WHWTs (3/10) was 
172 (range 154–184) months from birth. 
Table 2 All-cause and CIPF-specific survival times of 13 deceased CIPF WHWTs. 
 All-cause survival 
n=13/13 
(median and range) 
CIPF-specific survival 
n=7/13 
(median and range) 
From birth (months) 160 (123-188) 163 (155-170) 
From onset of clinical signs (months) 27 (2-51) 32 (2-51) 
From diagnosis (months) 13 (0-40) 11 (0-40) 
CIPF, canine idiopathic pulmonary fibrosis; WHWT, West Highland White Terrier. 
 
The KM curves for all-cause and CIPF-specific survival from onset of clinical 
signs are presented in Figure 4. 
  
Figure 4 Kaplan-Meier survival curves for all-cause survival (dotted line) and canine 
idiopathic pulmonary fibrosis (CIPF)-specific survival (solid line) of West Highland 
White Terriers (WHWTs) with CIPF from onset of clinical signs. Censored animals 
(for all-cause survival, WHWTs alive at study endpoint; for CIPF-specific survival, 
WHWTs alive and those who died of non-CIPF-related causes) are presented as 
circles. 
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Based on the Cox regression model for all-cause survival adjusted for dog′s 
age at study inclusion, the HR for risk of death in WHWTs with CIPF from 
birth relative to control WHWTs was 4.6 (95% CI 1.05–19.74, P= 0.04) and 
from study inclusion 4.4 (95% CI 0.94-20.5, P= 0.06). The HR for age in the 
multivariate Cox model from birth was 0.66 (95% CI 0.42–1.04, P= 0.08) 
and from study inclusion 1.93 (95% CI 1.25–2.98, P= 0.003). KM curves for 
survival of WHWTs with CIPF and control WHWTs from birth and from 
study inclusion are presented in Figure 5. 
 
  
Figure 5 (A). Kaplan-Meier (KM) survival curves for all-cause survival of West Highland 
White Terriers (WHWTs) with canine idiopathic pulmonary fibrosis (CIPF) (dotted 
line), and control WHWTs (solid line) from birth. Censored animals (WHWTs alive at 
study endpoint) are presented as circles. (B). KM survival curves for all-cause 
survival of WHWTs with CIPF and control WHWTs from study inclusion.  
No statistically significant prognostic factors were identified (Table 3). In 
addition, no significant effects of the rate of change in repeated-measure 
variables on the risk of CIPF-related death were detected (Table 4). 
A B
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Table 3 Cox regression analysis of the effects of prognostic variables on CIPF-
specific/all-cause survival in WHWTs with CIPF. 
Variable  
(unit change) 
N CIPF-specific 
survival 
HR (95% CI) 
P All-cause survival 
HR (95% CI) 
P 
PaO2 mmHg (10) 15 0.60 (0.21-1.72) 0.34 1.20 (0.58-2.46) 0.63 
PaCO2 mmHg (1) 15 0.96 (0.75-1.23) 0.75 1.02 (0.86-1.21) 0.78 
P(A-a)O2 mmHg (10) 14 1.59 (0.67-3.73) 0.29 0.93.(0.51-1.68) 0.81 
ET-1 pg/mL (1) 10 1.11 (0.70-1.75) 0.67 0.91 (0.59-1.42) 0.69 
HU (100) 10 0.71 (0.08-5.98) 0.75 0.69 (0.27-1.76) 0.44 
Severity of radiographic 
bronchointerstitial pattern 
(severe) 
15 2.68 (0.29-24.4) 0.38 0.66 (0.20-2.21) 0.50 
Presence of radiographic 
alveolar pattern (yes) 
15 1.87 (0.36-9.74) 0.46 1.51 (0.46-4.95) 0.50 
CIPF, canine idiopathic pulmonary fibrosis; WHWT, West Highland White Terrier; HR, hazard 
ratio; CI, confidence interval; PaO2, partial pressure of oxygen in arterial blood; PaCO2, partial 
pressure of carbon dioxide in arterial blood; P(A-a)O2, alveolar-arterial oxygen gradient; ET-1, 
serum endothelin-1 concentration; HU, Hounsfield unit (describing overall density of lung 
parenchyma in high-resolution computed tomography image). 
Table 4 Logistic regression analysis of the effects of change over time in repeated-
measure parameters on CIPF-specific death in 12 WHWTs with CIPF. 
Parameter (unit change) OR 95% Cl 
PaO2 mmHg (1) 0.85 0.62-1.15 
PaCO2 mmHg (1) 0.88 0.62-1.24 
P(A-a)O2 mmHg (1) 1.15 0.88-1.49 
Hematocrit % (1) 1.37 0.78-2.34 
Erythrocytes 1012/L (0.1) 1.21 0.89-1.65 
Hemoglobin g/L (1) 1.12 0.91-1.40 
MCV fL (1) 0.61 0.28-1.36 
Neutrophils 109/L (1) 1.13 0.82-1.54 
Lymphocytes 109/L (0.1) 0.96 0.80-1.15 
Eosinophils 109/L (0.1) 0.72 0.38-1.34 
Monocytes 109/L (0.1) 0.97 0.64-1.48 
Thrombocytes 109/L (10) 0.90 0.76-1.07 
CIPF, canine idiopathic pulmonary fibrosis; WHWT, West Highland White Terrier; OR, odds ratio; 
CI, confidence interval; PaO2, partial pressure of oxygen in arterial blood; PaCO2, partial 
pressure of carbon dioxide in arterial blood; P(A-a)O2, alveolar-arterial oxygen gradient; MCV, 
mean corpuscular volume. 
 
5.3 6MWT  
The 6MWD and the variables measured before and after walking in CIPF and 
control WHWTs (Study I) are presented in Table 5.  
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Table 5 Pre-and post-walking 6MWT characteristics in six WHWTs with CIPF and in five 
control WHWTs, given as median and range. 
Characteristic CIPF WHWT Control WHWT P 
Pre-HR( bpm)  107 (80-120) 114 (92-144) 0.13 
Post-HR (bpm) 108 (96-146) 126 (112-144) 0.18 
 P= 0.04 P= 0.32   
Pre-body T (°C) 38.7 (38.5-39.9) 39.0 (38.0-39.1) 0.93 
Post-body T (°C) 38.7 (38.5-39.2) 38.7 (38.3-39.2) 0.84 
 P= 0.47 P= 0.58  
Pre-SpO2 (%) 96 (87-100) 98 (96-98) 0.13 
Post-SpO2 (%) 97 (86-100) 98 (93-99) 0.79 
 P= 0.49 P= 0.46  
Pre-PaO2 (mmHg) 56.7 (49.4-64.9) 101.8 (82.0-108.0) 0.01 
Post-PaO2 (mmHg) 55.8 (37.7-61.8) 86.3 (82.0-110.0) 0.01 
 P= 0.08 P= 0.47  
Pre-PaCO2 (mmHg) 31.8 (26.1-36.9) 30.4 (27.4-34.0) 1.00 
Post-PaCO2 (mmHg) 28.5 (25,3-34,5) 32.7 (27.8-33.9) 0.35 
 P= 0.17 P= 0.14  
Pre-P(A-a)O2 (mmHg) 55.7 (45.3-70.0) 14.5 (12.2-23.8) 0.01 
Post-P(A-a)O2 (mmHg) 61.2 (53.8-82.4) 22.6 (7.8-35.3) 0.01 
 P= 0.08 P= 0.47  
6MWD (m) 398 (273-519) 492 (420-568) 0.05 
6MWT, six-minute walk test; CIPF, canine idiopathic pulmonary fibrosis; WHWT, West Highland 
White Terrier; HR, heart rate; SpO2, oxygen saturation measured by pulse oximetry; PaO2, 
partial pressure of oxygen in arterial blood; PaCO2, partial pressure of carbon dioxide in arterial 
blood; P(A-a)O2, alveolar-arterial oxygen gradient; 6MWD, six-minute walk distance. 
Comparisons between diseased and healthy groups using Mann-Whitney U-test; paired pre- and 
post-walking comparisons using Wilcoxon test. 
In diseased animals, PaO2 seemed to have a moderate positive correlation 
with 6MWD, although only statistically significant at 10% (Kendall’s tau-b = 
0.69, P= 0.06). Nine to 11 months after the first 6MWT, 4 of the 5 WHWTs 
with IPF had a reduced 6MWD relative to their initial visit. However, the 
difference between 6MWD at the first visit (median 399 m, range 309–519 
m) and 6MWD at the control visit (median 375 m, 230–478 m) was 
significant only at 10% (P = 0.08). 
5.4 BALF PROTEOMIC ANALYSIS  
In 2D-DIGE analysis (Study II), 18 protein spots were detected as 
differentially expressed in BALF of control dogs relative to expression in both 
groups of diseased dogs (CB dogs and CIPF WHWTs). In addition, one 
protein spot was significantly differentially expressed only between CIPF and 
healthy control dogs. For identification and further analysis, 9 protein spots 
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that were upregulated and 4 that were downregulated in both groups of 
diseased dogs and the one protein spot upregulated in the CIPF dogs were 
chosen based on their appearance in silver stained gel. Of the 9 proteins for 
which expression was upregulated, 5 were identified as complement C3, 
alpha-1-antitrypsin, apolipoprotein A-1, haptoglobin, and transketolase. The 
one protein for which expression was upregulated in the CIPF dogs was 
identified as β-actin. For the 4 proteins for which expression was 
downregulated, lysozyme C was identified. Verification of 2D-DIGE results 
was performed with Western blot analysis. Expression of β-actin was also 
detected in dogs with CB during the verification analysis. Therefore, further 
analysis with 2-D Western blots was performed, revealing that the expression 
pattern of β-actin protein among the dogs with CB was slightly different 
among individual dogs. 
 
5.5 P-SMAD2, LTBP-1, AND FIBRILLIN-2 
IMMUNOREACTIVITY IN FIBROTIC LUNGS 
A summary of immunostaining results of proteins linked to TGF-β signaling 
activity (P-Smad2), TGF-β storage (LTBP-1), and extracellular matrix 
regulation (fibrillin-2) in control WHWT, CIPF WHWT, human IPF/UIP, 
and human NSIP lungs (Study III) is presented in Table 6.  
Table 6 Localization and intensity of P-Smad2, LTBP-1 and fibrillin-2 immunoreactivity in 
control WHWT, CIPF WHWT, and human UIP and NSIP lungs. 
 P-Smad2 LTBP-1 Fibrillin-2 
 Alveolar 
area 
Bronchial 
epithelium 
Alveolar 
area 
Peribroncho- 
vascular 
Alveolar 
area 
Peribroncho-
vascular 
Control WHWT +/- +++ +/- +/- +/- ++ 
CIPF WHWT +++ +++ + ++ + ++ 
UIP +++ +++ +++ ++ ++ ++ 
NSIP +++ +++ + ++ + ++ 
WHWT, West Highland White Terrier; CIPF, canine idiopathic pulmonary fibrosis; UIP, human 
usual interstitial pneumonia; NSIP, human non-specific interstitial pneumonia. Immunoreactivity 
score: -, absent; +/-, absent or very mild; +, mild; ++, moderate; +++, intense immunostaining. 
5.5.1 P-SMAD2 IMMUNOREACTIVITY AND CORRELATION OF THE 
PERCENTAGE OF P-SMAD2- POSITIVE NUCLEI WITH ARTERIAL 
PARTIAL PRESSURE OF OXYGEN LEVELS  
In CIPF samples, a high amount of P-Smad2 immunoreactivity was mainly 
observed in the altered alveolar epithelium. In healthy control WHWTs, only 
low amounts of immunoreactivity were seen in the alveolar wall cells (Table 
6). Bronchial epithelial cells in all groups showed a high amount of positivity 
Results 
38 
(Table 6). In human NSIP samples, P-Smad2 immunoreactivity was observed 
in the altered alveolar epithelium lining the alveolar wall (Table 6) and in 
mononuclear inflammatory cells of the thickened alveolar and 
peribronchovascular interstitium. In human UIP samples, as previously 
reported (Khalil et al. 1996, Leppäranta et al. 2012), strong TGF-β signaling 
activity, indicated by intense P-Smad2 immunoreactivity, was seen in 
hyperplastic epithelial cells overlying the fibroblastic foci and in parenchyma. 
P-Smad2 immunoreactivity (calculated as the percentage of positive 
alveolar cell nuclei in the alveolar area) was significantly (P= 0.01) increased 
in WHWTs with CIPF (median 71%, range 40-82%) relative to healthy 
WHWTs (13%, 2-17%). No differences were seen between human UIP and 
NSIP groups (P= 0.14). A moderate negative correlation existed between 
PaO2 values and P-Smad2 immunoreactivity in WHWTs with CIPF (P= 
0.095, τ= 0.44). 
5.5.2 LOCALIZATION AND INTENSITY OF LTBP-1 
IMMUNOREACTIVITY 
In WHWTs with CIPF, moderate granular immunoreactivity was observed in 
altered alveolar epithelial cells and mild multifocal staining in the alveolar 
interstitium. In addition, moderate granular staining in bronchial epithelial 
cells and mild staining in smooth muscle cells of bronchiolar and vascular 
walls were present in diseased WHWTs (staining of alveolar and 
peribronchovascular areas was quantified separately) (Table 6). In healthy 
WHWTs, only very mild or absent alveolar staining and very mild 
peribronchovascular staining were observed (Table 6). In NSIP, mild to 
moderate LTBP-1 immunoreactivity was noted in alveolar interstitial and 
peribronchovascular areas (Table 6). Staining of altered alveolar epithelium 
in NSIP samples was less prominent than the intense immunostaining seen 
in UIP samples. In UIP, as previously reported (Leppäranta et al. 2012), 
moderate immunoreactivity was also seen in fibroblastic foci and the 
surrounding parenchymal tissue.  
A significant increase (P= 0.02) in intensity of LTBP-1 immunoreactivity 
in peribronchovascular areas was seen in WHWTs with CIPF (median 1, 
range 0.5-2) relative to healthy WHWTs (0.5, 0.25-0.5). No statistical 
difference emerged in alveolar staining between WHWTs with CIPF and 
healthy WHWTs (P= 0.31). Between UIP and NSIP groups, no differences 
were detected in alveolar (P= 0.10) or peribronchovascular immunoreactivity 
(P= 0.26). 
5.5.3 LOCALIZATION AND INTENSITY OF FIBRILLIN-2 
IMMUNOREACTIVITY 
Fibrillin-2 localized most intensively in peribronchial and perivascular areas 
and also multifocally in the alveolar interstitium of CIPF WHWT lung 
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samples. Absent or very mild alveolar immunoreactivity was seen in healthy 
WHWTs (Table 6). The alveolar immunoreactivity seen in CIPF WHWTs was 
generally less intense than in human UIP and NSIP samples. In NSIP, mild 
multifocal alveolar interstitial immunoreactivity was noted (Table 6). In UIP, 
mild to moderate fibrillin-2 immunoreactivity was observed in the thickened 
parenchymal tissue, especially in fibroblastic foci, as reported previously 
(Leppäranta et al. 2012). Peribronchovascular staining was present at a 
similar intensity in all sample groups (Table 6). 
No statistical differences were detected in fibrillin-2 alveolar 
immunoreactivity between control WHWTs and CIPF WHWTs (P= 0.24) or 
between UIP and NSIP groups (P= 0.77), nor was a difference observed in 
peribronchovascular immunoreactivity (P= 0.65 and P= 0.63, respectively).  
 
5.6 ACTIVIN A AND ACTIVIN B IMMUNOREACTIVITY IN 
FIBROTIC LUNGS AND DIFFUSE ALVEOLAR 
DAMAGE 
A summary of activin A and B immunostaining results in control WHWT, 
CIPF WHWT, and ARDS dog lungs (Study IV) is presented in Table 7. 
Table 7 Localization and intensity of activin A and activin B immunoreactivity in lung 
tissue of control WHWTs, CIPF WHWTs, CIPF WHWTs with AE/DAD, and 
ARDS/DAD dogs.  
 AEC I AEC II Mononuclear 
inflamm. cells 
Bronchial 
epithelium 
Alveolar 
edema 
 act A act B act A act B act A act B act A act B act A act B 
Control WHWTs - +/- +/- +/- + + + +++ n/a n/a 
CIPF WHWTs - + - +++ + + +/- +++ n/a n/a 
CIPF WHWTs with AE/DAD - ++ +/- +++ + + + +++ + ++ 
ARDS/DAD dogs - ++ - +++ + ++ + +++ ++ +++ 
act A, activin A; act B, activin B; CIPF, canine idiopathic pulmonary fibrosis; WHWT, West 
Highland White Terrier; AE, acute exacerbation; DAD, diffuse alveolar damage; ARDS, acute 
respiratory distress syndrome; AECI, alveolar epithelial cell with appearance of type I cell; AECII, 
alveolar epithelial cell with appearance of type II cell. Immunoreactivity score: -, absent; +/-, 
absent or very mild; +, mild; ++, moderate; +++, intense immunostaining; n/a, not applicable. 
5.6.1 ACTIVIN A LOCALIZATION AND INTENSITY OF 
IMMUNOREACTIVITY 
Absent or very mild activin A immunoreactivity was observed in the altered 
alveolar epithelium in CIPF samples or on the alveolar wall surface of control 
lung samples (Table 7). Mild positive immunostaining in bronchial epithelial 
cells and in mononuclear inflammatory cells was seen in less than half of the 
CIPF samples, comparable with findings in control lung samples. The regions 
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of alveolar edema seen in CIPF samples with AE also showed mild positive 
immunostaining for activin A (Table 7). In ARDS lungs, the alveolar 
epithelial lining and the activated alveolar epithelial cells were negative. Mild 
positive immunoreactivity was seen in mononuclear inflammatory cells and 
in the bronchial epithelium, and moderate positive staining of alveolar 
edema was observed (Table 7). 
No significant difference between groups was detected in immunostaining 
score of AEC type I cells (P= 1.00), AEC type II cells (P= 0.48), mononuclear 
inflammatory cells (P= 0.27), bronchial epithelium (P= 0.43), or alveolar 
edema (P=0.08).  
 
5.6.2 ACTIVIN B LOCALIZATION AND INTENSITY OF 
IMMUNOREACTIVITY AND WESTERN BLOT ANALYSIS 
In control animals, intense activin B immunoreactivity was observed in the 
bronchial epithelium, whereas alveolar surface cells remained negative 
(Table 7). In WHWTs with CIPF, intense immunoreactivity was observed in 
pathologically altered AECII cells and in bronchial epithelial cells (Table 7). 
In WHWTs with CIPF and concurrent AE, also the alveolar edema showed 
intense fine granular staining. In the CIPF and control groups, mild 
immunoreactivity was observed in mononuclear inflammatory cells (Table 
7).  In ARDS lungs, intense activin B immunoreactivity was seen in altered 
AECII cells of samples representing the proliferative phase of ARDS and on 
the surface of denuded alveolar walls, alveolar edema, and hyaline 
membranes of samples representing the exudative phase.  
A significant increase in AECII staining intensity score was seen in lungs 
of WHWTs with CIPF (median 3, range 2.5- 3) relative to healthy WHWTs 
(0.5, 0- 0.5) (P=0.04) and in lungs of WHWTs with CIPF and concurrent AE 
(3, 3-3) relative to healthy WHWTs (P=0.02). No significant difference was 
seen in AECII immunoreactivity between ARDS (3, 2- 3) and healthy dogs 
(P= 0.23) or between CIPF with AE and ARDS dogs (P= 1.00). No significant 
difference between study groups was seen in AECI (P= 0.08), mononuclear 
inflammatory cells (P= 0.11), bronchial epithelium (P= 1.00), or alveolar 
edema (P= 0.46) immunostaining results.  
Activin B was detected by Western blot analysis in 2/2 BALF samples 
from WHWTs with CIPF and concurrent AE. In addition, a weak band was 
observed in 2/4 BALF samples from WHWTs with CIPF but no AE. None of 
the six BALF samples of control WHWTs had detectable levels of activin B. 
Monomeric activin B (~15 kDa) was mainly detected in the BALF samples 
due to the dissociation of the dimeric form of activin B (~ 30 kDa). A 
representative image of the Western blot results is shown in Figure 6.  
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Figure 6 Western blot results of protein expression of activin B monomer of ~ 15 kDa in 
bronchoalveolar lavage fluid of West Highland White Terriers (WHWTs) with canine 
idiopathic pulmonary fibrosis (CIPF) and concurrent acute exacerbation (AE) and 
diffuse alveolar damage (DAD), lines 1 and 2; WHWTs with CIPF but no AE/DAD, 
lines 3, 4, and 5; and healthy control WHWTs, lines 6, 7, and 8. As a positive 
control (POS), recombinant activin B was used. 
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6 DISCUSSION 
6.1 CLINICAL COURSE AND SURVIVAL 
CIPF is a disease occurring in older WHWTs, and the magnitude of its effect 
on lifespan as well as the natural history of the disease had been previously 
unclear (Corcoran et al. 1999), as no prospective follow-up studies with 
controls had been published. In our follow-up study (Study I), we 
demonstrated that CIPF has significant negative impact on life expectancy of 
affected WHWTs. This finding was supported by both of our age-adjusted 
survival models, with risk for death from birth being 4.6 times higher and 
from study inclusion 4.4 times higher in diseased animals than in controls, 
although the risk in the latter model was statistically significant only at 10%.  
The median survival after diagnosis in WHWTs with CIPF was 1 year, but 
some dogs lived up to 3 years (Study I). In humans, the median survival after 
diagnosis of IPF is 2-3 years (Raghu et al. 2011) and after diagnosis of fibrotic 
NSIP 6-13.5 years (Kim et al. 2006). The median survival time from onset of 
clinical signs in the CIPF-related death group was quite high, 2.7 years, but 
varied greatly, from only 2 months to 4.3 years (Study I). This variation 
indicates that CIPF in WHWTs may have either a rapid or a slow disease 
progression, as also seen in human IPF (Kim et al. 2006). Five WHWTs with 
CIPF in our follow-up study were euthanized due to acute dyspnea. In human 
IPF, these acute respiratory deteriorations of unidentifiable cause are termed 
AEs of IPF (Collard et al. 2007). The AE term is suitable also for CIPF, as 
necropsy of these dogs did not reveal an alternative explanation for acute 
dyspnea and 4/5 of these dyspneic dogs had DAD in lungs, which is reported 
in humans as a common terminal histopathological finding related to AEs of 
IPF (Rice et al. 2003). Despite intensive care, mortality of human AE 
patients is up to 80% (Kim et al. 2006). For ethical reasons and because of 
the expected poor outcome, benefits of treatment efforts should be carefully 
considered in CIPF dogs experiencing AE.  
Since chronic hypoxemia can cause erythrocytosis, and weight loss could 
occur due to poor condition, we followed the hematocrit values and weight of 
the CIPF WHWTs during disease progression. Neither weight loss nor 
change in hematocrit was seen (Study I). Severe malnutrition is also not a 
feature of human IPF (Nathan et al. 2013).  
Thoracic radiograph features varied during the disease independently of 
clinical signs and were not useful in evaluating disease progression (Study I). 
In humans, chest radiographs also correlate poorly with disease severity 
(Kim et al. 2006). In addition, evaluation of other emerging diseases in 
thoracic radiographs of CIPF WHWTs, such as infections or neoplasms, 
could be challenging, as changes seen in radiographs already at the time of 
diagnosis were so marked. Although none of the deceased WHWTs with 
 43 
CIPF in our study had primary lung tumors detected postmortem, in man 
bronchogenic carcinoma occurs with increased frequency in lungs affected by 
IPF (Ley et al. 2011), and pulmonary neoplasms are also reported to occur in 
cats with an IPF-like condition (Cohn et al. 2004, Williams et al. 2004). 
During the course of the disease, a declining trend in PaO2 values of CIPF 
WHWTs was detected (Study I). The decrease between the first and last 
PaO2 values in dogs that died of CIPF-related causes was significant, as was 
the increase in P(A-a)O2 values. However, in some CIPF WHWTs, temporary 
increases in arterial oxygenation were noted, and some owners described a 
temporal improvement in clinical signs. As our study design did not allow 
systematic evaluation of the treatment effect on survival or on clinical signs 
due to individual treatment protocols, the impact of medication on these 
improvements cannot be assessed. However, human IPF is unresponsive to 
the treatments used in our study (Raghu et al. 2011), while patients with 
NSIP usually benefit from corticosteroids (Park et al. 2009). Although 
repeated measurements of arterial blood gas values proved to be the most 
valuable tool for evaluating disease progression in CIPF WHWTs, some 
animals with very low PaO2 values survived surprisingly long due to 
excellent adaptation and slow deterioration in oxygenation capacity.  
6.2 6MWT 
Exercise intolerance is one of the main clinical signs of IPF in both dogs 
(Heikkilä et al. 2011a) and humans (Raghu et al. 2011). However, objective 
evaluation of exercise intolerance in older non-athletic pet dogs can be 
difficult. Therefore, a noninvasive 6MWT with age- and breed-matched 
controls for more comparable results of exercise performance was applied 
(Study I). In human medicine, from the clinical perspective, the advantages 
of 6MWT are that it can be performed with no special equipment or training 
and all but the most severely ill patients are able to perform it (ATS 2002, du 
Bois et al. 2011). For the same reasons, 6MWT is promising for veterinary 
use, especially as dogs might need hours of training to walk on a treadmill 
and some might not cooperate at all (Kittleson et al. 1996). However, low 
6MWD itself is non-specific and non-diagnostic, and thorough clinical 
examinations are warranted to identify the cause of the impairment (ATS 
2002). In our study, we showed that 6MWT was easy to perform and well-
tolerated in WHWTs with CIPF. The 6MWD in diseased animals was reduced 
relative to that in control dogs. In addition, the 6MWD in CIPF WHWTs was 
reduced at the 9- to 11-month control visit, albeit significant only at 10%. The 
PaO2 seemed to correlate positively with 6MWD, and therefore, the 6MWD 
could serve as a noninvasive means of monitoring lung function in WHWTs 
with CIPF. However, this finding requires confirmation in larger sample sets. 
In pre- and postwalking variables, the only significant change was a higher 
postwalking heart rate in WHWTs with CIPF. The short delay when taking 
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the postwalking arterial sample may influence the arterial blood sample 
results. We did not detect a significant difference in SpO2 between controls 
and WHWTs with CIPF, nor did we found significant postwalking oxygen 
desaturation. Previous studies have reported a difference in oxygen 
saturation between healthy dogs and dogs with pulmonary disease (Swimmer 
and Rozanski 2011) as well as post-walking oxygen desaturation in a group of 
old healthy beagles (Gault et al. 2010). This discrepancy in results may be 
due to different breed or device; in our study, pulse oximeter seemed to be a 
rather unreliable indicator of a decline in PaO2 in WHWTs with CIPF. In 
human patients with IPF, desaturation during the test distance walked and 
6MWD decline over time have been linked to a higher risk of death (Lama et 
al. 2003, Caminati et al. 2009, du Bois et al. 2011).  Due to our low sample 
size, we were unable to use these parameters in prognostic factor analysis.  
6.3 EVALUATION OF POTENTIAL PROGNOSTIC 
FACTORS AND BIOMARKERS 
For CIPF, no prognostic factors of survival are currently known and no 
biomarkers are in clinical use. A noninvasive biomarker from BALF or serum 
would be highly beneficial for more practical CIPF diagnosis, for evaluating 
disease severity and progression, and for differentiation of CIPF from CB. 
For human IPF, several individual predictors of survival have been reported 
during the last decades. These include clinical predictors, such as age, 
medical imaging predictors, physiologic predictors, pathological predictors, 
and biomarker predictors from blood and BALF (Ley et al. 2011). However, a 
clinically useful predictor model for human IPF is lacking (Ley at al. 2011). In 
our study, we aimed to evaluate potential prognostic factors affecting the 
survival of diseased dogs (Study I) and to identify potential biomarkers for 
CIPF from BALF by comparing BALF protein expressions in CIPF, CB, and 
healthy dogs (Study II). 
No significant prognostic factors for CIPF were identified among the 
chosen variables, which is most likely due to our low sample size. However, a 
slight indication of high PaO2 having a protective effect on survival was 
noted, supporting the use of arterial blood gas measurements in CIPF follow-
up. In addition, a slight indication of high P(A-a)O2 being a risk factor 
emerged. In humans, an increase in P(A-a)O2 is associated with earlier IPF 
mortality (King et al. 2005). No significant effects of change in repeated 
measure parameters on the risk of CIPF-related death were noted. However, 
a slight indication of a higher risk of CIPF-related death could be seen with 
an increase in hematocrit, hemoglobin, and erythrocyte values. Some 
potentially interesting prognostic factors, including 6MWD, BALF cell counts 
(Heikkilä et al. 2011a), BALF PIIINP concentrations (Heikkilä et al. 2012), 
and pulmonary hypertension (Schober and Baade 2006), which have been 
shown to be altered in CIPF WHWTs and to have prognostic value in human 
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IPF (Lammi et al. 1999, Caminati et al. 2008, Kinder et al. 2008, Andersen et 
al. 2012), could not be included in our study due to low sample size. 
The search for biomarkers from complex biological samples, such as 
BALF, is challenging, as highly abundant blood-derived proteins interfere 
with the detection of locally produced and more pathologically relevant 
proteins present in lower amounts (Govender et al. 2007, Kinnula et al. 
2009). To obtain quantitative data on differences in the BALF proteome 
between CIPF, CB, and healthy dogs, we applied the 2D-DIGE method. 
However, no CIPF specific biomarkers were found. This probably reflects the 
difficulty in detecting the low-abundance fraction of the BALF proteome, 
where the proteins of interest in pulmonary fibrosis are likely to be found 
(Goveder et al. 2007). We did, however, detect five proteins that were 
upregulated and one that was downregulated in CIPF and CB dogs relative to 
controls.  In addition, one protein, β-actin, was initially recognized to be 
upregulated only in the CIPF group, but further analysis revealed that the 
protein was heterogeneously expressed in each of the CB dogs, and therefore, 
not detected in 2D-DIGE. Thus, the extent of expression of β-actin in CB dogs 
remains unknown. Of the seven differentially expressed proteins, β-actin is 
part of the cellular cytoskeleton, complement C3 is part of the complement 
system, α-1-antitrypsin, apolipoprotein A-1, and haptoglobin are anti-
inflammatory proteins, transketolase is involved in glucose metabolism, and 
lysozyme is part of the innate immune system. β-actin is one of the most 
frequently differentially expressed proteins found in various proteomic 
analyses (Petrak et al. 2008), reflecting more its involvement in the common 
stress response than its role as a true biomarker (Wang et al. 2009). Many 
proteins identified in BALF are plasma proteins, as in our study complement 
C3, α-1-antitrypsin, apolipoprotein A-1, and haptoglobin, and their increase 
in BALF is likely to be caused by increased permeability of the lung 
epithelium during CIPF and CB. However, these proteins are also produced 
locally in lung tissue to provide extra protection to the lung during disease 
processes (Wattiez and Falmagne 2005). Increased levels of complement 
proteins (Magi et al. 2002), α-1-antitrypsin (Noël-Georis et al. 2001), and 
haptoglobin (Magi et al. 2002) as well as downregulation of apolipoprotein 
A-1 (Kim et al. 2010) have been detected in BALF from humans with IPF. 
Although no specific biomarkers for CIPF were found, the proteins with 
upregulated expression indicated activation of anti-inflammatory and 
glycolytic pathways, involvement of the complement cascade, and presence 
of cytoskeletal proteins in lung tissue of dogs with CIPF and CB. 
6.4 TGF-β-RELATED MOLECULAR PATHWAYS  
The central role of TGF-β-mediated fibrosis is well established in human IPF 
(Koli et al. 2008), and activation of TGF-β pathways has been suggested to 
take part in the pathophysiology of CIPF (Krafft et al. 2011a, 2012). TGF-β 
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has a wide variety of biological functions that contribute to development of 
fibrosis, such as recruitment of inflammatory cells, regulation of synthesis of 
ECM components, and induction of EMT in epithelial cells (Khalil et al. 1991, 
Rosendahl et al. 2001, Willis and Borok 2007). As CIPF shares clinical and 
histopathological features with human IPF/UIP and NSIP (Heikkilä et al. 
2011a, Syrjä et al. 2013), we wanted to compare also the TGF-β-related 
molecular pathways between canine and human diseases.  
We demonstrated that enhanced TGF-β signaling, indicated by increased 
P-Smad2 immunoreactivity in lungs of WHWTs with CIPF, is part of the 
molecular pathophysiology of CIPF and that the majority of TGF-β-
responsive cells were located in the altered alveolar epithelium, as seen in 
both UIP and NSIP (Study III). The finding of increased TGF-β1 signaling in 
CIPF lungs was confirmed in the study by Krafft et al. (in press 2014).  The 
alveolar localization of active TGF-β signaling with earlier reported marked 
atypia of AECII in CIPF (Syrjä et al. 2013) further supports the importance of 
abnormally activated alveolar epithelium in the pathogenesis of CIPF. The 
PaO2 in WHWTs with CIPF seemed to correlate negatively with P-Smad2 
immunoreactivity, possibly indicating that the fibrotic disease progression is 
related to more active TGF-ß signaling. 
The ECM is not just a storage site for TGF-β, but a place in which the 
structural components of ECM, most notably LTBPs and fibrillins, 
participate in the regulation of TGF-β availability and activation (Massam-
Wu et al. 2010, Horiguchi et al. 2012, Todorovik and Rifkin 2012). The 
expression of ECM proteins LTBP-1 and fibrillin-2 has been shown to be 
upregulated in human IPF lung tissue (Leppäranta et al. 2012), but their role 
in CIPF or human NSIP had not been previously studied. In healthy human 
lungs, LTBP-1 and fibrillin-2 are only present around blood vessels and in 
arterial and bronchial smooth muscle cell layers (Leppäranta et al. 2012). We 
showed similar staining localization of LTBP-1 and fibrillin-2 in the lungs of 
control WHWTs (Study III). An interesting difference was seen in LTBP-1 
staining intensity of AECs between UIP and NSIP. In NSIP, very mild or 
absent AEC staining was noted relative to the intense AEC staining seen in 
UIP samples, suggesting a different role of altered epithelium in these two 
human interstitial lung diseases. The alveolar LTBP-1 immunolabeling in 
CIPF WHWTs resembled that seen in UIP samples. As there was a 
significantly higher peribronchovascular LTBP-1 immunoreactivity in the 
lungs of CIPF WHWTs than in those of control WHWTs, the small airway 
component might be more important in CIPF. Previously, the presence of 
bronchiolar-derived epithelium on the peribronchiolar alveolar septa was 
detected by immunohistochemistry in the histological study of CIPF in 
WHWTS (Syrjä et al. 2013), indicating that the pathogenesis of CIPF involves 
epithelial differentiation or migration at the bronchio-alveolar junction. 
Although AECs play the key role in the fibrotic process seen in human IPF, it 
has also been shown that small airways are structurally altered and may 
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contribute to the remodeling events in both IPF/UIP and NSIP (Figueira de 
Mello et al. 2010). 
The aberrant activation of developmental pathways has been suggested to 
be feature of the molecular pathobiology of human IPF (Sellman et al. 2008), 
and re-appearance of fibrillin-2, a developmental gene, has been previously 
detected in UIP lung tissue (Leppäranta et al. 2012). We detected alveolar 
interstitial immunoreactivity of fibrillin-2 in all diseased groups and 
especially in the fibroblastic foci in UIP lungs, as reported earlier 
(Leppäranta et al. 2012). Our finding may indicate that developmental 
pathways are activated also in CIPF and NSIP. Microarray analysis of CIPF 
lung tissue has previously shown upregulation of genes linked to 
developmental pathways (Krafft et al. 2013). However, as alveolar interstitial 
immunostaining of fibrillin-2 seen in CIPF lungs was generally less intense 
than that seen in human samples, fibrillin-2 expression might be a less 
prominent feature of CIPF.  
Activins are cytokines belonging to the TGF-β superfamily, and they are 
speculated to be the key intermediary in TGF-β1-mediated fibrosis (Patella et 
al. 2006, Hedger and de Kretser 2013). Strong evidence supports the 
importance of activins and their endogenous inhibitor, follistatin, in 
inflammation and fibrotic response, although studies regarding the role of 
activin B are sparse (Hedger et al. 2011, Hedger and de Kretser 2013, de 
Kretser et al. 2013).  No studies on the role of activins in any canine 
respiratory disease have been published. We aimed to investigate the 
presence of activin A and activin B in normal canine lung tissue and to 
determine whether activins have a role in CIPF, in its AEs, and in canine 
ARDS (Study IV). The ARDS group was incorporated into the study since 
ARDS and AEs of CIPF are both histopathologically characterized by DAD 
(deClue and Cohn 2007, Study I) and since activin A has been suggested to 
take part in human IPF (Matsuse et al. 1996, de Kretser et al. 2012) and 
ARDS (Apostolou et al. 2012).  
We demonstrated that activin B is strongly expressed in the pathologically 
altered alveolar epithelium in lungs of WHWTs with CIPF as well as in ARDS 
lungs. This novel finding supports the importance of activin B in fibrosis and 
in the pathological alteration of AEC. As activins share the same intracellular 
Smad signaling pathway with TGF-βs  (Itoh et al. 2000, Rosendahl et al. 
2001), some of the increased Smad signaling seen in CIPF lung tissue (Study 
III) could be due to activin signaling. Based on the observed strong bronchial 
activin B immunoreactivity seen in control lung samples, the cellular origin 
of the activin B in the canine lung tissue under normal physiological 
conditions seems to be mainly the bronchial epithelium.  Activin A, in 
contrast, seemed not to be a major protein expressed by canine lung tissue in 
either the normal or diseased state. This result contradicts findings in human 
IPF and ARDS (Matsuse et al. 1996, Apostolou et al. 2012) and in 
experimental bleomycin-induced mouse models (Matsuse et al. 1995) in 
which activin A overexpression has been demonstrated. An explanation for 
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this discrepancy could be that since there are significant species-specific 
differences in the baseline tissue expression of the βA and βB subunits 
(Hedger and de Kretser 2013) the expression of the βA subunit in canine lung 
tissue might be low overall. 
Since AEs of CIPF often lead to euthanasia (Study I) and AEs of human 
IPF have very poor outcome despite treatment efforts (Collard et al. 2007, 
Meltzer and Noble 2008, van den Blink et al. 2010), predicting who is at risk 
of developing AE would be highly beneficial to guide early therapeutic 
approaches.  Some biomarkers for human IPF AEs have been suggested, such 
as high serum levels of alpha-defensin (Mukae et al. 2002), SL2 protein 
(Tajima et al. 2003), and KL-6 (Yokoama et al. 1998), but none is in clinical 
use. A recent publication demonstrated that increased serum concentrations 
of activins A and B predicted higher mortality in critical care patients with 
acute respiratory failure (de Kretser et al. 2013). 
Our findings of intense activin B and mild to moderate activin A 
immunoreactivity of alveolar edema in CIPF/AE and ARDS lung samples 
(Study IV) suggest that activins as soluble proteins might also be present in 
the serum of dogs suffering from acute respiratory failure and that especially 
activin B could serve as a potential biomarker of lung injury. The potential of 
activin B to serve as a marker of alveolar epithelial cell damage is further 
supported by our finding of activin B in the BALF of both of the CIPF 
WHWTs suffering from AE. No detectable levels were seen in control BALF 
samples from healthy WHWTs. Interestingly, two of the four BALF samples 
from WHWTs with CIPF but no AE showed very weak bands for activin B 
relative to the AE samples and two were negative. Further studies with 
alternative methods, such as ELISA, and with larger sample sets are needed 
to confirm and quantify the levels of activin B in BALF and sera of dogs with 
CIPF to better assess its use as an indicator of ongoing or higher risk of 
alveolar epithelial injury.  
Since TGF-β itself is not an ideal candidate for antifibrotic therapies, 
especially in chronic conditions, based on such harmful effects as profound 
immune dysregulation, seen in mice lacking TGF-β1, other therapeutic 
strategies targeting the TGF-β system are of great interest (Böttinger et al. 
1997, Leask and Abraham 2004). The potential of the activin-follistatin 
system as a therapeutic target in treating serious illnesses, e.g. different 
fibrotic diseases and ARDS, remains unknown, but blocking the actions of 
activins by an endogenous inhibitor, such as follistatin, might prove to be 
beneficial (Patella et al. 2006, Hedger and de Kretser 2013). 
6.5 STUDY LIMITATIONS 
The main limitation in the follow-up study (Study I) was the low number of 
animals, resulting in a lack of significance in prognostic factor analysis for 
CIPF. The low number of animals is mainly due to CIPF being an uncommon 
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disease of mostly one breed and the diagnosis, as well as the verification of 
health, requiring invasive procedures. In addition, the median age of the 
healthy control WHWT group was slightly younger, and only three deaths 
occurred in the control group. However, the median follow-up time was 
similar in both groups, and the age was taken into account in the survival 
analysis.  Overall, we consider our thoroughly examined healthy WHWT 
group and the histopathologically or HRCT-confirmed CIPF WHWT group 
unique for the descriptive study of the natural history of CIPF in WHWTs. 
For the biomarker search from BALF (Study II), the number of samples 
from each group; CIPF WHWT, CB dogs, and controls, was small. However, 
the 2D-DIGE technique incorporates a pooled internal standard that 
minimizes the experimental variation associated with gel-to-gel comparisons 
(Lilley and Friedman 2004). Therefore, the changes in protein expression 
between the groups more likely reflect true biological differences. In 
addition, we chose not to include WHWTs in the CB or healthy control group 
to avoid possible subclinical CIPF carriers, and to further enhance 
characterization of CIPF and CB, we analyzed only protein spots detected in 
all of the samples in a particular group. The CB and control dogs were all 
adults and as the differences in protein profiles between CIPF and CB dogs 
were similar, breed and age were not likely to affect results. 
For both immunohistochemistry studies (Studies III and IV), the main 
limitation was the low number of control lung samples, reflecting the 
difficulty in accessing normal lung tissue from old WHWTs. However, we 
chose not to include lung samples from other breeds, as CIPF is mainly breed 
predisposed. In addition, for Study IV, only two BALF samples from CIPF 
WHWTs suffering from AE were available for activin B analysis. This is 
mostly due to ethical reasons, as antemortem BALF samples are usually not 
taken from dogs with severe respiratory distress. The results of Western blot 
analysis of activin B in BALF of WHWTs with CIPF are therefore only 
indicative and require confirmation in larger sample sets. 
6.6 FUTURE RESEARCH PROSPECTS 
IPF is a devastating disease of unknown etiology and pathogenesis in both 
humans and dogs. No curative treatment exists (Coward et al. 2010, Heikkilä 
et al. 2011a, Raghu et al. 2011). For human IPF, it has been shown that 
mortality rates from IPF have increased and are expected to continue to rise 
in the future (Olson et al. 2007). In addition, as a spontaneous animal model 
for human IPF is lacking (Gauldie and Kolb 2008), research on naturally 
occurring fibrosing lung disease in animals, such as CIPF, can shed light also 
on human research. Elucidating the molecular pathophysiology of human 
and canine IPF is crucial for better understanding of the disease mechanisms 
and for developing new treatment strategies and diagnostic markers. Because 
CIPF is mainly breed predisposed, genetic studies are needed to reveal the 
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complex genetic factors involved and later possibly to help dog breeders 
select healthier dogs for breeding purposes. Genetic studies on CIPF in 
WHWTs could also yield valuable information to research on the familial 
form of human IPF. In addition, studies on lung fibrosis in other dog breeds 
should be conducted to determine whether multiple fibrosing interstitial lung 
disease subtypes exist in dogs. Our findings regarding the natural history and 
molecular pathways of CIPF and the similarities with human IPF provide a 
good base for the planning of future research.  
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7 CONCLUSIONS 
1. CIPF has a significant negative impact on life expectancy of 
diseased WHWTs. The median CIPF-specific survival of WHWTs 
after the onset of clinical signs was 2.7 years, but individual 
survival varied considerably, suggesting that CIPF in WHWTs 
may have either a rapid or a slow disease progression. No 
prognostic factors were identified. The 6MWD proved to be an 
easy and noninvasive parameter to evaluate lung function and 
level of exercise intolerance in WHWTs with CIPF. 
 
2. No potential biomarkers specific for CIPF were found in 
proteomic analysis of BALF. However, six proteins were detected 
as differentially expressed in CIPF WHWTs and CB dogs relative 
to healthy control dogs, suggesting a common cellular response 
to disease processes in these two otherwise different lung 
diseases.  
 
3. Increased TGF-β signaling and expression of its ECM regulatory 
proteins LTBP-1 and fibrillin-2 were shown to be components of 
the molecular pathophysiology of CIPF, as also seen in human 
IPF/UIP and NSIP. The novel finding of upregulation of activin 
B in CIPF lung tissue and in diffuse alveolar damage suggests 
that activin B is part of the pathophysiology of CIPF and might 
act as a potential marker of alveolar epithelial damage. 
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